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ABSTRACT 
Hill, Natasha Tremayne. Biomedical Sciences Ph.D. Program, Wright State University 
2015. Vitamin D receptor and 1α, 25-dihydroxyvitamin D3 mediated regulation of 
ΔNp63α. 
 
 1, 25-dihydroxyvitamin D3 (VD3), the ligand for the Vitamin D Receptor 
(VDR), functions to both inhibit cell growth and promote cell survival.  High-dose VD3 is 
being utilized as a cancer preventive therapy for melanoma, breast and colorectal cancers, 
without a complete understanding of VD3/VDR signaling.  Np63, considered to be a 
proto-oncogene, is overexpressed in non-melanoma skin cancers (NMSCs), induces VDR 
gene expression and promotes keratinocyte proliferation, and may serve to exacerbate 
non-melanoma skin cancer.  The objective of this dissertation was to determine whether 
VDR/VD3 signaling promotes keratinocyte proliferation by up-regulating Np63. I 
showed that VDR increases Np63 expression at both the transcript and protein level.  
Furthermore, low doses of VD3 led to increased Np63 protein expression and 
keratinocyte proliferation in a VDR-dependent manner, while higher doses of VD3 failed 
to increase Np63 expression and instead resulted in reduced proliferation.  I found that 
VD3-mediated increases in Np63 protein occur partially via activation of Akt. 
Simultaneous inhibition of Akt and VDR knockdown blocked the proliferative effects of 
low dose VD3 but enhanced the growth suppressive effects of high dose VD3.  p38 
MAPK was also found to increase Np63 expression in a VD3-dependent manner 
leading to increased keratinocyte proliferation. Taken together, my data provided critical 
insights into VD3 signaling and bring to light a potentially detrimental effect of VD3 
treatment as a chemotherapeutic adjuvant.  
 iv 
 Previous studies have shown that VDR and p63 are overexpressed independently 
in NMSC, but no correlation of the two proteins expression has yet been made.  Here I 
show that increased expression of VDR correlates with overexpression of p63 in a 
number of NMSC subtypes. p53 mutant proteins are also expressed in patients with 
NMSC.  Moreover, mutant p53 was shown to regulate the transcriptional activity of the 
VDR, converting the effects of VDR from pro-apoptotic to anti-apoptotic. Here I show 
that endogenous VDR and mutant p53 form a complex suggesting they functionally 
interact with each other. Furthermore, loss of mutant p53 alone led to a significant 
reduction in Np63 transcript and protein levels, while the loss of mutant p53 and VDR 
together led to a further reduction in Np63 protein. Loss of mutant p53 abrogated 
VD3-mediated increases in Np63 protein, suggesting that mutant p53 is involved in 
VD3-mediated increases in Np63 protein expression. Taken together my data suggest 
that the absence of mutant p53 could potentially restore VD3 chemotherapeutic potential 
in NMSC.   
 This study provides mechanistic insight into how VD3 can exert both pro-
proliferative and pro-apoptotic effects by elucidating the differential dose effects of VD3 
on Np63 protein levels. Delineation of the mechanisms by which VD3 exerts its effect 
on Np63 will be critical for determining the future of VD3 in cancer therapies. 
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I. INTRODUCTION 
A. Non-Melanoma Skin Cancer 
 Skin cancer is the most commonly occurring cancer in the United States with 
approximately 3 million new cases of non-melanoma skin cancer (NMSC) each year 
(Rogers et al., 2015). NMSC are classified as squamous cell carcinomas, basal cell 
carcinomas, angiosarcoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, 
dermatofibrosarcoma protuberans, merkel cell carcinoma, and sebaceous gland 
carcinoma. (Boukamp, 2005; Nakayama, 2010). Basal cell carcinoma (BCC) occurs in 
the basal layer, which is the deepest layer in the epidermis (Boukamp, 2005; Nakayama, 
2010). BCC are slow growing tumors that rarely metastasize and are most frequently 
found in fair-skinned individuals (Arlette & Trotter, 2004; Green & Marks, 2004; Chen et 
al., 2013; Baheti et al., 2015). Unfortunately, there are no identified precursor lesions for 
BCC (Boukamp, 2005; Baheti et al., 2015). Squamous cell carcinomas (SCC) arise in the 
squamous cell keratinocytes that make up the outer layers of the epidermis (Boukamp, 
2005; Nakayama, 2010). Unlike BCC, there are several known precursor lesions to SCC 
(Boukamp, 2005; Ratushny et al., 2012; Rigel & Stein Gold, 2013). The most common 
precursor lesion to SCC is Actinic Keratosis (AK) (Ratushny et al., 2012; Rigel & Stein 
Gold, 2013). AK lesions are scaly plaques, which are generally pink, tan or brown in 
color (Ratushny et al., 2012; Rigel & Stein Gold, 2013). In rare cases AK lesions resolve 
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spontaneously, but the majority of AKs lesions lead to SCC (Ratushny et al., 2012; Rigel 
& Stein Gold, 2013). Acantholytic Actinic Keratosis (AA) is a variant of AK that has lost 
the adhesion proteins, which make up desmosomes, thus leading to a loss of connectivity 
between squamous keratinocytes (Goldberg et al., 1994; Barnaby et al., 1997). Another 
variant of AK is Bowenoid Actinic Keratosis (BA), which has well defined edges and 
generally occurs as a solitary plaque (Goldberg et al., 1994).   Hyperplastic Actinic 
Keratosis (HA) is an advanced stage of AK that is similar in appearance to AK but is 
thicker in size (Goldberg et al., 1994).  SCC in situ, also called Bowen disease, is a 
precancerous lesion that can progress to invasive SCC (Goldberg et al., 1994; Ratushny 
et al., 2012; Rigel & Stein Gold, 2013). Invasive SCC, especially cases that arise from 
tumors on the eyelid, lead to the majority of SCC associated metastases and are 
responsible for approximately 3,000 deaths annually (Boukamp, 2005; Nakayama, 2010).  
 Risk factors for skin cancer include ultraviolet (UV) radiation, inherited 
syndromes such as albinism, xeroderma pigmentosum and nevoid basal cell carcinoma, a 
weakened immune system, medications such as vandetanib, vemurafenib and 
voriconzole, and infection with the human papillomavirus (HPV) (Young, C., 2009; 
Gordon, 2013; Surdu, 2014).  Most skin cancers are attributed to UV exposure (Young, 
C., 2009; Gordon, 2013; Surdu, 2014). UV radiation also induces the production of VD3, 
which is an essential nutrient of the body and has been shown to reduce cancer incidence 
(Boukamp, 2005; Nakayama, 2010; Reichrath & Reichrath, 2013). Studies have shown 
that VD3 prevents NMSC by inhibiting the hedgehog-signaling pathway in BCC and 
modulating p53 in SCC (Reichrath & Reichrath, 2013). One of the hallmarks of non-
melanoma skin cancers is an increased expression of the proto-oncogene Np63 
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(Bircan et al., 2006; Sakiz et al., 2009), which directly up-regulates the Vitamin D 
Receptor (VDR) expression (Kommagani et al., 2009).  
B. The Skin 
 The skin is the largest organ in the body and serves to protect the body from 
hazards in the environment (Bikle, 2012). The skin consists of the dermis and epidermis 
(Bikle, 2012). The epidermis is where non-melanoma skin cancer arises (Bikle, 2012). 
There are 4 layers of the epidermis. The stratum basale or basal layer is the lowest layer 
of the epidermis resting on the basal lamina, which separates the epidermis from the 
dermis (Bikle, 2012).  The stratum basale consists of the basal layer keratinocytes, which 
are highly proliferative (Bikle, 2012). These keratinocytes express the highest levels of 
Np63 in the skin (Figure 1) (Koster et al., 2004). Characteristic markers of the basal 
layer are keratin 5 and keratin 14 (Romano et al., 2012; Giamboi-Miraglia et al., 2015).  
The next layer of the epidermis is the stratum spinosum or spinous layer (Figure 1), 
which provides structural reinforcement (Bikle, 2012). Characteristic markers of the 
spinosum are keratin 1 and keratin 10 (Taylor et al., 2012; Giamboi-Miraglia et al., 
2015). Above the spinosum is the stratum granulosum or granulosum layer, which 
functions as a water barrier by preventing water exchange from outside to inside of the 
body and vice versa (Figure 1) (Bikle, 2012). A characteristic marker of the granulosum 
is loricrin (Giamboi-Miraglia et al., 2015). The outermost layer of the epidermis is the 
stratum corneum (Figure 1) (Bikle, 2012). The corneum functions as a barrier between 
the body and the outside world (Bikle, 2012). VDR is expressed throughout the epidermis 
and plays an important role in the proliferation of the basal layer and differentiation to the  
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Figure 1: Cross section of the human epidermis. The epidermis consists of four layers; 
the basal layer, spinous layer, the granulosum layer and the corneum. Markers that are 
used to define the individual layers are indicated. Np63 is highly expressed in the 
basal layer of the epidermis, but decreases as the cell begin to differentiate into the upper 
layers of the epidermis.  
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spinosum and granulosum (Reichrath & Reichrath, 2013). Np63 is primarily 
expressed in the basal layer (Romano et al., 2012).   As the epidermis differentiates into 
the spinousum and subsequently the granulosum, the expression of Np63 is 
dramatically reduced to undetectable levels in upper layer of the epidermis (Koster et al., 
2004).  
C. Np63  
 The transcription factor p63 belongs to the p53 family of proteins (Yang, A. et al., 
1998). p63 contains an N-terminal transactivation domain, a central DNA binding 
domain (DBD) and a C-terminal oligomerization domain (Yang, A. et al., 1998), all of 
which share high sequence homology with the tumor suppressor p53 (Pagano et al., 
2013). The transcription factor p63 is transcribed from chromosome 3 position q28 
(Yang, A. et al., 1998). There are 6 primary isoforms of p63 which arise due to 
alternative promoter usage and 3’ splicing (Yang, A. et al., 1998). The p63 gene has two 
promoters, the first, known as P1, is located 5’ of exon 1 while the second, known as P2, 
is located in intron 3 (Figure 2) (Yang, A. et al., 1998). Use of the P1 promoter drives the 
transcription of the TAp63 isoforms with a full-length N-terminal transactivation domain, 
whereas use of the internal P2 promoter yields the transcription of the Np63 isoforms 
harboring a truncated N-terminal transactivation domain (Figure 2), with 14 unique 
amino acids (Yang, A. et al., 1998). Furthermore, differential 3’ splicing of p63 yields , 
β, and γ isoforms of both TAp63 and ΔNp63 proteins (Figure 2) (Yang, A. et al., 1998).  
 The p63 protein is essential for the formation and proliferation of the epidermis 
along with other stratified epithelia, which was clearly demonstrated in p63 null mice  
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Figure 2: p63 isoforms. Schematic showing the p63 gene comprising the two promoter 
sites, 3’ splicing segments and diagram of the six main p63 isoforms. Transactivation 
domain denoted as TA, DNA-binding denoted as DBD, oligomerization domain labeled 
as OD, sterile alpha motif denoted SAM and transactivation inhibitory domain labeled as 
TI. 
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 (Mills et al., 1999; Yang, A. et al., 1999). These mice were born lacking skin, limbs and 
died shortly after birth due to dehydration (Mills et al., 1999; Yang, A. et al., 1999). 
Although TAp63 initiates epithelia stratification, Np63 plays a crucial role in 
maintaining epithelial stem cell proliferation (Mills et al., 1999). The most abundant and 
physiologically relevant p63 isoform is Np63, which is widely expressed in the basal 
layers of stratified epithelium where it primarily functions in maintaining epithelial 
integrity (Koster et al., 2004). 
 Np63 is considered a proto-oncogene and is overexpressed in many cancers 
such as basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) (Reis-Filho et 
al., 2002; Lo Muzio et al., 2005; Bircan et al., 2006). Mechanistically, the overexpression 
of Np63 in cancer has been shown to inhibit the transcription of PTEN leading to 
increased tumor cell survival mediated by enhanced AKT activation (Leonard et al., 
2011). Furthermore, Np63 positively regulates the epidermal growth factor receptor, 
which has been shown to increase pancreatic cancer cell proliferation (Danilov et al., 
2011). Interestingly, although loss of p63 led to the reduced growth of pancreatic cancer 
cells (Danilov et al., 2011), loss of p63 was also shown to increase cancer progression in 
prostate, bladder and breast cancer (Medina-Franco et al., 2002; Urist et al., 2002) 
indicating a complex role for p63 in mediating cancer progression. Moreover, loss or 
inhibition of Np63 is associated with increased motility and cell invasion (Senoo et 
al., 2002; Sniezek et al., 2004; Barbieri et al., 2006; Carroll et al., 2006; Kommagani et 
al., 2009).  Although increased expression of Np63 is considered a biomarker for 
Squamous Cell Carcinoma of the lung (Massion et al., 2003), reduced Np63 
expression is an indicator of poor prognosis in cancers such as Basal-like Breast 
 8 
Carcinomas, Lung Squamous Cell Carcinomas, Lung Adenocarcinomas and Esophagus 
Squamous Cell Carcinomas (Graziano & De Laurenzi, 2011). To date, there is little 
known about the mechanism that leads to increase or loss of Np63 expression in 
cancer. Therefore, this dissertation intends to identify the upstream modulators that lead 
to increase Np63 expression.  
D. Mutant p53 
 Several studies have shown that various mutant isoforms of p53 inhibit Np63 
activity leading to increased motility (Adorno et al., 2009; Liu et al., 2009; Muller et al., 
2009; Girardini et al., 2011; Liu et al., 2011).  The tumor suppressor p53 is transcribed 
from the tumor protein p53 (TP53) gene located on the short arm of chromosome 17 
locus p13.1 (McBride et al., 1986). The p53 gene location is one of the many sites in the 
genome that shows more frequent ultraviolet (UV) induced mutations (Dumaz et al., 
1993; Ziegler et al., 1993). Interestingly, while guanine to thymidine (G-T) mutation are 
the most common mutant p53 mutation in lung cancer, cytosine to thymidine (C-T) 
mutation which are induced by UV radiation also show a high frequency in lung cancer 
(Hainaut & Pfeifer, 2001). The p53 tumor suppressor is a major regulator of cellular 
functions such as cell cycle arrest, senescence or apoptosis (Zuckerman et al., 2009). 
These functions are prevented in cancer development allowing cells to grow in an 
uncontrolled manner (Shaulian et al., 1992; Zuckerman et al., 2009). Interestingly, p53 is 
mutated in half of all human cancers, with most non-melanoma skin cancers expressing at 
least one mutant allele of p53 (Zuckerman et al., 2009). There are several different types 
of p53 mutations, but mutations that alter DNA binding of p53 are the most common 
(Freed-Pastor & Prives, 2012). DNA binding domain mutants affect the wild type p53 
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function in two ways (Cho et al., 1994). The first mechanism involves mutation of key 
residues in the DNA binding domain (DBD) that render the protein incapable of binding 
p53 responsive elements (p53RE) in p53 target genes (Pavletich et al., 1993; Cho et al., 
1994; Bullock et al., 1997).These types of mutants are known as contact mutants and 
include R248Q, R273C and R282W p53 proteins (Bullock et al., 1997). The second 
mechanism in which DNA binding is altered results from a change in the DNA sequence 
of p53, which leads to modification in the protein folding of p53 (Cho et al., 1994). These 
mutations destabilize the p53 structure and inhibit its binding to its target genes (Cho et 
al., 1994; Bullock et al., 1997). The most highly studied of this type of p53 mutant, 
known as a conformation mutant, is the p53 R175H protein (Bargonetti et al., 1997; Di 
Como et al., 1999; Chicas et al., 2000; Marin et al., 2000; Gaiddon et al., 2001; 
Torgeman et al., 2001; Di Agostino et al., 2006; Haupt, S. et al., 2009; Stambolsky et al., 
2010; Liu et al., 2011; Sutherland et al., 2012). While some p53 mutants retain some 
residual wild type p53 activity, others inhibit the activity of wild type p53, and/or exhibit 
gain of function (GOF) properties (Bargonetti et al., 1997; Di Como et al., 1999; Chicas 
et al., 2000; Marin et al., 2000; Gaiddon et al., 2001; Torgeman et al., 2001; Di Agostino 
et al., 2006; Haupt, S. et al., 2009; Stambolsky et al., 2010; Liu et al., 2011; Sutherland 
et al., 2012). GOF mutant p53 induce cell proliferation, chemoresistance and increase cell 
invasion. The six most commonly observed hot spot GOF mutations in p53 occur at sites 
R175, G245, R248, R249, R273 and R282 (Harris & Hollstein, 1993; Cho et al., 1994; 
Petitjean et al., 2007). These mutations are found in 30% of p53 mutants observed in 
human cancers (Harris & Hollstein, 1993; Cho et al., 1994; Petitjean et al., 2007). In 
most cases, mutant p53 protein is stable and accumulates in the tumor, which is one of  
 10 
 
Figure 3: Sites and occurrence of p53 mutations. Schematic of p53 gene with the most 
evolutionarily conserved sites indicated in blue boxes. The hot spot p53 mutations are 
labeled in bold.  The p53 mutation found in A431 cells is highlighted in blue and the p53 
mutation found in the HaCaT cell line are highlighted in red. 
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the hallmarks of cancer (Siegel et al., 2012). Interestingly, the most phylogenetically 
conserved residues are the site at which p53 is most heavily mutated (Figure 3) (Harris & 
Hollstein, 1993; Cho et al., 1994; Petitjean et al., 2007). One of the most notable 
functions of GOF mutant p53 proteins is their ability to inhibit p63 protein function 
leading to increased tumor formation and invasion (Girardini et al., 2011; Liu et al., 
2011; Neilsen et al., 2013). Mutant p53 employs multiple mechanisms to promote 
tumorigenesis including regulating the activity of its family members wild-type p53, p63 
and p73 (Liu et al., 2009; Zuckerman et al., 2009; Girardini et al., 2011; Neilsen et al., 
2013). Both mutant p53 and Np63 have been shown to lead to increased cancer cell 
proliferation (Shaulian et al., 1992; Gaiddon et al., 2001; Li, Y. & Prives, 2007; Adorno 
et al., 2009; Liu et al., 2009; Marine & Berx, 2009; Muller et al., 2009; Rokaeus et al., 
2010; Girardini et al., 2011; Neilsen et al., 2011; Neilsen et al., 2013). Notably, GOF p53 
H179Y has been shown to increase cancer cell proliferation and is expressed in human 
keratinocyte cell line HaCaT (Mueller et al., 2001; Yang, D. et al., 2007; Li, X. et al., 
2012). Although, it is not known whether p53 H179Y physically interacts with Np63, 
overexpression of p53 H179Y leads to an increase in the cell cycle regulators cyclin A1 
and Cdk4 (Yang, D. et al., 2007) thus promoting progression through the cell cycle. A 
previous study showed that mutant p53 alters the transactivation of the Vitamin D 
Receptor (VDR) such that it inhibits the expression of VDR targets involved in apoptosis 
and induces the expression of VDR targets that have the potential to promote 
tumorigenesis (Stambolsky et al., 2010). Mutant p53 thereby converts VDR action from 
an inducer of apoptosis to an enhancer of cancer cell survival (Stambolsky et al., 2010).   
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E. 1α, 25-dihydroxyvitamin D3 (VD3) and VDR  
 1α, 25-dihydroxyvitamin D3 (VD3) plays major roles in calcium and phosphate 
homeostasis in the human body (Bikle, 2012). In cancer and in non-cancerous cells, VD3 
induces differentiation and apoptosis (Deeb et al., 2007; Bikle, 2012). The secosteroid 
hormone VD3 is produced in the body via the skin or Pre-VD3 is obtained through the diet 
and processed in the liver and kidney to produce VD3 (Bikle, 2012). Production of VD3 
starts in the skin with the isomerization of 7-dehydrocholesterol to cholecalciferol, which 
is induced by UVB radiation at a wavelength between 290-315 nm (Bikle, 2012). 
Cholecalciferol (Pre-VD3) exits the skin to produce the active form of VD3 with reactions 
that occur in the liver and followed by the kidney or stays in the skin to generate the 
biologically active form of VD3 (Bikle, 2012). In the liver or skin, cholecalciferol is 
converted to 25α -hydroxyvitamin D3 (calcidiol) by CYP27A1 (Bikle, 2012). Further 
conversion to 1α, 25-dihydroxyvitamin D3 (calcitriol) by CYP27B1 occurs in the skin 
and kidney (Bikle, 2012). Calcitriol is the biologically active form of VD3 and is 
responsible for most of the VD3 induced gene regulation (Bikle, 2012). Calcitriol levels 
are down-regulated by its target gene CYP24A, an enzyme that removes the hydroxide at 
position 1 to reform calcidiol (Bikle, 2012).   
 The Vitamin D Receptor (VDR) is a ligand-dependent transcription factor. VD3, 
the most biologically active form of Vitamin D, is the ligand that binds VDR (Deeb et al., 
2007; Yang, D. et al., 2007; Haussler et al., 2011). It is unclear if VD3 binds VDR in the 
cytoplasm and then moves into the nucleus or if VD3 binds VDR in the nucleus to 
regulate gene transcription (Deeb et al., 2007; Yang, D. et al., 2007; Haussler et al., 
2011). In the presence of VD3, VDR heterodimerizes with the retinoic X receptor (RXR)   
 13 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4: VDR/Vitamin D3 Genomic Signaling. Diagram showing VDR and vitamin D 
genomic signaling, which results in VD3 target gene transactivation. Transactivation of 
VD3 target genes occurs following the binding of VD3 to VDR. This binding leads to 
VDR/RXR complex formation and target gene binding near the VDRE.  
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Figure 5: Non-genomic VDR/Vitamin D3 signaling. Schematic of VD3 non-genomic 
signaling, which shows VD3 can induce the opening of Ca
2+ channel, activate GPCR or 
lead to the activation of signaling kinase pathways. 
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(Deeb et al., 2007; Yang, D. et al., 2007; Haussler et al., 2011). Once in a complex, VDR 
binds to the vitamin D response elements (VDRE) in the promoters of its target genes 
involved in proliferation and apoptosis to regulate their expression (Figure 4) (Deeb et 
al., 2007). VDR is also known to have non-genomic or rapid response activity in the 
presence of VD3 (Figure 5) (Haussler et al., 2011).  Interestingly, it has been suggested 
that the confirmation in which VDR binds VD3 dictates whether VD3/VDR will induce 
genomic or non-genomic signaling (Norman et al., 1997; Norman et al., 2002). The non-
genomic activity of VD3 leads to the activation of G-proteins, protein kinase C (PKC), 
phosphoinositide 3 kinase (PI3K) and phospholipase C (PLC) (Haussler et al., 2011).  
 VD3 has been explored as an anticancer agent due to its role in apoptosis and 
inhibition of angiogenesis (Asagami et al., 1996; Zhao et al., 1997; Iseki et al., 1999; 
Chung et al., 2006). Interestingly, VD3 has also been shown to promote survival via 
activation of the Akt and p38 MAPK pathway (Zhuang & Burnstein, 1998; Zhang, Y. et 
al., 2006; Zhang, X. & Zanello, 2008). Furthermore, increased Akt and p38 MAPK 
activation has been shown to increase the expression of Np63 (Barbieri et al., 2003). 
Both Akt and p38 MAPK activation by VD3 occur within minutes of VD3 treatment 
suggesting that VD3 activates the two kinases via the rapid response pathway (Zhuang & 
Burnstein, 1998; Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008).  
F. Akt 
 Akt, also known as protein kinase B (PKB), is a kinase that inhibits and activates 
several cellular processes within mammalian cells leading to increased cell survival 
(Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). In addition, Akt can inhibit 
apoptosis by preventing the release of cytochrome c from the mitochondria and by 
 16 
inactivating the pro-apoptotic proteins BAD and procaspoase-9 via phosphorylation 
(Barbieri et al., 2003; Altomare & Testa, 2005). Another mechanism by which Akt 
inhibits apoptosis is through the down-regulation of the tumor suppressor protein p53 
(Mayo & Donner, 2002; Zhou & Hung, 2002). This is accomplished by the 
phosphorylation of the p53 negative regulator mouse double minute 2 (Mdm2) by Akt 
which leads to the stabilization of mdm2, thereby reducing p53 levels. Akt also increases 
cell survival by phosphorylation-induced inhibition of cell cycle inhibitors p21 and p27 
(Mayo & Donner, 2002; Zhou & Hung, 2002). Furthermore, previous work has shown 
that activated Akt leads to an increase in cyclin D1, cyclin D3 and cyclin E, critical for 
progression through the cell cycle (Muise-Helmericks et al., 1998). Another mechanism 
by which Akt promotes cell survival is by increasing the levels of the proto-oncogene 
Np63. More importantly, activated Akt could prove to be a link that connects VD3-
mediated increase in cell survival with increased expression of ΔNp63α in NMSC. 
 Akt is expressed as three distinct kinases known as Akt 1 (PKBα), Akt 2 (PKBβ) 
and Akt 3 (PKBγ) (Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). These three 
Akt kinases are transcribed from three different gene loci but all three of the kinases have 
similar functions and are activated in the same manner (Altomare & Testa, 2005; 
Vanhaesebroeck et al., 2012).  Akt is activated in response to a variety of different 
stimuli such as cytokines, growth factors and mitogens (Altomare & Testa, 2005; 
Vanhaesebroeck et al., 2012). These stimuli activate a receptor tyrosine kinase (RTK) or 
G-protein coupled receptor (GPCR) leading to activation of phosphoinositide-3-kinase 
(PI3K) (Altomare & Testa, 2005; Vanhaesebroeck et al., 2012).  At the cellular or 
nuclear membrane, activated PI3K phosphorylates phosphatidylinositol (3,4)-
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bisphosphate (PI(3,4)P2) to form phosphatidylinositol (3,4,5)-bisphosphate (PI(3,4,5)P3) 
(Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). Next, Akt and Phosphoinositide-
dependent kinase-1 (PDK1) bind PI(3,4,5)P3 via a Pleckstrin homology domain (PH 
Domain), a domain that specifically recognizes and binds PI(3,4,5)P3 (Altomare & Testa, 
2005; Vanhaesebroeck et al., 2012). Once bound to PI(3,4,5)P3, PDK1 phosphorylates 
threonines located at positions 308, 309 and 305 in the kinase domain of Akt1, Akt 2 and 
Akt 3, respectively (Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). Following 
threonine phosphorylation, mammalian target of rapamycin complex 2 (mTOR2) 
phosphorylates Akt on a serine located at the C-terminal regulatory domain leading to 
full activation of Akt (positions 473, 474 and 472 for Akt 1, Akt 2 and Akt 3, 
respectively) (Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). Once fully 
activated, Akt phosphorylates its downstream targets to increase cell survival. A 
schematic representation of Akt activation can be found in Figure 6.  
G. p38 MAPK 
 Like Akt, p38 mitogen activated protein kinase (p38 MAPK) is activated in 
response to VD3 (Buitrago, C. G. et al., 2006; Buitrago, C. & Boland, 2010).  
Furthermore, p38 MAPK activation was shown to increase ΔNp63α protein levels 
(Cheng et al., 2009). There are four p38 MAPK proteins, which are transcribed from 
different gene loci (Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). The four kinases 
share about 60% sequence homology with each other (Zarubin & Han, 2005; Cuadrado & 
Nebreda, 2010). They consist of p38α, also referred to as p38, p38β, p38γ and p38δ 
(Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). The p38α MAPK is ubiquitously 
expressed while p38β, p38γ and p38δ are only expressed in the brain, skeletal muscle and  
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Figure 6: AKT signaling pathway. Akt is activated in response to a number of 
mitogens. The mitogens bind the receptor tyrosine kinase thereby activating 
phosphoinositide-3-kinase. Activation of phosphoinositide-3-kinase then leads to the 
conversion of phosphatidylinositol (3,4)-bisphosphate to phosphatidylinositol (3,4,5)-
bisphosphate. Finally, phosphatidylinositol (3,4,5)-bisphosphate recruits PDK and Akt to 
the membrane for full activation of Akt following phosphorylation by PDK and mTOR2.   
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endocrine glands, respectively (Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). The 
p38 MAPKs have overlapping substrate specificity and therefore up or down-regulates 
similar process in the individual tissues where they are expressed (Zarubin & Han, 2005; 
Cuadrado & Nebreda, 2010).  
 p38 is a kinase that regulates several cellular functions including protein 
degradation, protein cellular localization, mRNA stability, endocytosis, apoptosis, 
cytoskeleton dynamics, proliferation and cell migration (Zarubin & Han, 2005; Cuadrado 
& Nebreda, 2010). The mechanism by which p38 MAPK regulate these processes are 
diverse and in some cases extremely complex (Zarubin & Han, 2005; Cuadrado & 
Nebreda, 2010). For example, p38 MAPK can increase cell proliferation by 
phosphorylating the protein known as C-terminal end of membrane-associated 
metalloprotease TNFα-converting enzyme, a disintegrin and metalloproteinase domain 17 
(TACE/ADAM17) (Cuadrado & Nebreda, 2010). This phosphorylation promotes the 
release of transforming growth factor alpha (TGFα) ligand, thereby activating EGFR 
signaling. p38 can not only promote proliferation but can also promote apoptosis, cycle 
arrest or senescence via the stabilization of its target gene the tumor suppresser p53 
(Cuadrado & Nebreda, 2010). The mechanism(s) by which p38 promotes cell 
proliferation and cell death are thought to be cell type dependent or dependent on the 
method of p38 activation (Cuadrado & Nebreda, 2010). A number of mitogens such as 
growth factors, environmental stress and inflammatory cytokines are known to lead to the 
activation of p38 MAPK (Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). 
 The mitogens that activate p38 MAPK signaling pathway all lead to the same 
cellular downstream effect, the activation of MAP kinase kinase kinase (MAP3K) 
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(Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). There are several known MAP3K 
that are upstream of p38 MAPK. They consist of: apoptosis signal-regulating kinase 1 
(ASK1), dual-leucine-zipper-bearing kinase 1 (DLK1), TGFβ-activated kinase 1 (TAK1), 
thousand-and-one amino acid 1 and 2 (TAO), MAPK / extracellular signal-regulated 
kinases kinase 3 and 4 (MEKK3), and leucine zipper and sterile-α motif kinase 1 (ZAK1) 
(Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). The MAP3K are serine threonine 
kinases, which phosphorylate MAP kinase kinase (MAP2K), specifically MAP kinase 
kinase 3 and 6 (MKK3 and MKK6) (Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). 
Both MKK3 and MKK6 specifically phosphorylate all p38 MAPK isoforms on in the 
activation loop at a threonine glycine tyrosine sequence (Figure 7) (Zarubin & Han, 2005; 
Cuadrado & Nebreda, 2010). Additionally, the c-Jun N-terminal kinase (JNK) activator 
MKK4 can also activate p38α as shown in Figure 7. 
   Several studies have shown that VD3/VDR signaling can lead to increased cell 
proliferation via activation of the Akt pathway or through the activation of the p38 
MAPK signaling pathway (De Haes et al., 2003; Zhang, Y. et al., 2006; Zhang, X. & 
Zanello, 2008; Langberg et al., 2009). The mechanism underlying the regulation of 
Np63 expression and how this regulation is altered to increase cancer cell proliferation 
is poorly understood and very little is known regarding the role of mutant p53 in NMSC.  
Furthermore, VDR and VD3 have been implicated in cancer prevention leading to the 
need for a better understanding of the mechanism VDR/VD3 utilized to induce either 
proliferation or prevent cancer and in what context each phenotype induced. This 
dissertation delineates a mechanism by which VDR/VD3 and mutant p53 induce 
proliferation through the induction of Np63 and demonstrate that the expression levels  
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Figure 7: MAPK p38 signaling pathway. The MAPK p38 is activated by a number of 
stimuli, which binds receptor tyrosine kinases leading to the receptors activation. 
Following activation, the receptor tyrosine kinase will stimulate the activation of one or 
more MAP3Ks (ASK1, DLK1, TAK1, TAO, MEEK and ZAK). The MAP3K will 
phosphorylate one or more of the MAP2Ks (MKK3, MKK4 or MKK6) leading to the 
activation of the p38 upstream MAP2K. MAP2Ks phosphorylate p38 MAPK leading to 
its activation. 
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of both Np63 and VDR are elevated in NMSC.  
H. Significance  
 Np63 and mutant p53 are overexpressed in NMSC (Hibi et al., 2000; Choi et 
al., 2002; Di Como et al., 2002; Bircan et al., 2006; Sakiz et al., 2009). Furthermore, 
mutant p53 downstream targets play a role in the induction of proliferation and inhibition 
of apoptosis making mutant p53 harboring cancers problematic to treat. Identification of 
pathways that control tumor cell survival in the presence of GOF mutant p53 in cells that 
overexpress Np63 remains a major challenge. One method by which mutant p53  
action leads to increased proliferation and reduced apoptosis is mutant p53 mediated 
inhibitor  of p63 transcriptional activity or by the regulating VDR transactivation of VDR 
target genes (Gaiddon et al., 2001; Li, Y. et al., 2008; Liu et al., 2009; Stambolsky et al., 
2010; Lin et al., 2012). Our lack of understanding in regards to the mechanism by which 
Np63 is increased in a number of cancers makes it extremely difficult to manage 
cancers such as NMSC, which regularly reoccur, and express increased levels of 
Np63. The work presented herein demonstrates that both VDR and mutant p53 up-
regulate Np63 protein and transcript expression. Our proposed studies on the 
regulation of VDR/VD3 signaling through Np63 will represent novel mechanism by 
which VDR/VD3 lead to increased survival. Moreover, since several human cancers have 
mutant p53 and elevated Np63, examining the role of mutant p53 on the interplay 
between Np63 and VD3 signaling will provide a better understanding of the impact of 
VD3 use as a chemotherapeutic agent.  
 23 
I. Rationale  
 Np63 is overexpressed in most non-melanoma skin cancers (NMSCs) (Dumaz 
et al., 1993; Ziegler et al., 1993; Hibi et al., 2000; Choi et al., 2002; Di Como et al., 
2002; Bircan et al., 2006; Sakiz et al., 2009). Both Np63 and VDR are expressed in 
the basal level of the skin and were independently shown to be increased in non-
melanoma skin cancer (Hibi et al., 2000; Choi et al., 2002; Di Como et al., 2002; 
Mitschele et al., 2004; Reichrath et al., 2004; Bircan et al., 2006; Sakiz et al., 2009). 
Previous work from our laboratory showed that Np63 transcriptionally up-regulates 
the expression of VDR (Kommagani et al., 2006; Kommagani et al., 2009). To date, no 
group has investigated whether VDR can in turn up-regulate Np63.  VDR has 
genomic and non-genomic functions in the cell (Haussler et al., 2011). The genomic 
functions of VDR increases the transcription of its target genes such as CYP27B1 or 
CYP24A1 (Haussler et al., 2011). In contrast, the non-genomic functions of VDR lead to 
the activation of G-proteins, Protein Kinase C (PKC), Phosphoinositide 3-Kinase (PI3K) 
and Phospholipase C (PLC) at the cell membrane (Haussler et al., 2011). Previous studies 
have shown that VD3, the VDR ligand, leads to increased activation of both Akt and p38 
MAPK (Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008). Interestingly, both Akt and 
p38 MAPK have been shown to positively regulate the expression of Np63 (Ogawa et 
al., 2008; Cheng et al., 2009). Thus, VDR and VD3 could potentially increase the 
expression of Np63 through Akt or p38 MAPK. Lastly, a report by Stambolsky et al., 
2010 showed mutant p53 can directly interact with VDR in the presence of VD3 to 
activate expression of genes that contain the VDR response element (VDRE) in their 
promoter regions (HIRA, TGF-β1, CYP24A1 and CYP27B) (Stambolsky et al., 2010). 
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Preliminary evidence shows that there are three putative VDRE in the p63 gene promoter 
and one immediately downstream of the p63 gene.   Thus, mutant p53 could potentially 
modulate VDR transcriptional activity to increase the expression of Np63. In this 
study I will also test whether mutant p53 increases Np63 gene expression by 
modulating VDR.  
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II. MATERIALS AND METHODS 
A. Cell lines and Reagents 
 The non-tumorigenic immortalized human keratinocyte HaCaT cell line was 
obtained from Dr. Nancy Bigley (Wright State University) while the tumorigenic H-Ras 
transformed HaCaT II-4 cells were obtained from Dr. Nancy Colburn (National Cancer 
Institute). The squamous cell carcinoma cell line A431 was obtained from ATCC 
(Manassas, Virginia, USA). The three cell lines were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 8 % fetal bovine serum (FBS) and 250 U 
penicillin and 250 g streptomycin. The human embryonic kidney cell line HEK-293FT 
was obtained from Dr. Hakan Cam (Ohio State University). HEK-293FT cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % 
fetal bovine serum (FBS), 0.1 mM modified Eagle’s medium non-essential amino acids 
(NEAA), 6 mM L-glutamine, 1 mM modified Eagle’s medium sodium pyruvate, 500 
μg/mL geneticin and 250 U penicillin and 250 g streptomycin. Neonatal human 
epidermal keratinocytes (NHEK) were maintained in KGM-Gold media as per 
manufacturer’s instructions (Lonza, Walkersville, MD). The Akt inhibitor MK2206 and 
the p38 inhibitor BIRB-796 were purchased from Selleckchem (Houston, TX, USA). The 
p38 inhibitor SB202190 was purchased from Cell Signaling (Danvers, MA, USA). 1, 
25-dihydroxyvitamin D3 was maintained as a 100 μM stock in 100% ethanol (Cat # 
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17936, Sigma-Aldrich, St. Louis, MO). 1, 25-dihydroxyvitamin D3 treatments were 
done in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 8% charcoal 
stripped fetal bovine serum (FBS) and 250 U penicillin and 250 g streptomycin at a 
final EtOH concentration of 0.01%. Charcoal stripped fetal bovine serum was used 
because the serum is stripped of all lipophilic molecules such as VD3. 
B. mRNA Knockdown  
 VDR and p63 knockdown studies were conducted in HaCaT, HaCaT II-4, A431 
and NHEK cells were performed by two rounds of siRNA transfection using 
Lipofectamine RNAi-Max per manufacturer’s instructions (Life Technologies, Carlsbad, 
CA, USA). VDR and p63 siRNA used in this study were purchased from Qiagen 
(Valencia, CA, USA) and the target sequences used were previously validated 
(Kommagani et al., 2009).  Knockdown studies of p53 were conducted in HaCaT, HaCaT 
II-4 and A431 cells by performing two rounds of siRNA transfection using 
Lipofectamine RNAi-Max per manufacturer’s instructions (Life Technologies, Carlsbad, 
CA, USA). p53 siRNA used in this study was purchased from Qiagen (Valencia, CA, 
USA) against the  target sequence 5’-AAFFAAATTGCGTGTGG AGT-3’.  
C. Generation of HaCaT stable cell lines via lentivirus infection. 
 HaCaT-eGFP and HaCaT-Np63 stable cell lines were generated by infection 
of the parental HaCaT cells with lentivirus expressing eGFP or Np63 as previously 
described (Kommagani et al., 2009).  Briefly, virus production was performed using 
HEK-293FT cells seeded onto a 10 cm dish at 3x 106 cells per well.  Twenty-four hours 
later, cells were transfected with 4.6 μg of the HIV-1 gag and pol expressing lentivirus 
packing plasmid, 1.8 μg of the HIV-1 rev expressing lentivirus packing plasmid, 2.52 μg 
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of the vesicular stomatitis virus G glycoprotein pLP-VSVG plasmid and either 9 μg 
pLentiV6-eGFP or pLentiV6-ΔNp63α cDNA using Metafectene (München, Germany). 
At 24 hours post infection, HEK-293FT cell media was changed for virus production.  
Medium containing virus was collected at 72 hours post transfection, centrifuged to 
remove the debris and stored in 1.5 ml aliquots or used immediately to infect HaCaT 
cells. To generate stably expressing lines, parental HaCaT cells were seeded at 2x 105 
cells per well in two wells of a 6-well dish 24 hours prior to virus infection.  The next 
day, 1.5 ml of the ΔNp63α or eGFP lentivirus solution, 500 l of complete media and 10 
μg/ml of Polybrene (EMD Millipore, Billerica, MA, USA) were added directly to the 
parental cells.  Lentivirus infected HaCaT cultures were supplemented with fresh media 
at 24 hours post infection, and infected cells were subjected to blasticidin (10 mg/ml) 
(Life Technologies, Carlsbad, CA USA) selection initiated at 72 hours post-infection to 
obtain HaCaT stable cells expressing eGFP or Np63.  
D. Cell Immunofluorescence Staining 
 Cells were grown on sterile glass coverslips and fixed with 2% paraformaldehyde 
for 15 min. The coverslips were washed three times with PBS, permeabilized with 0.2% 
Triton X-100 diluted in PBS for 5 min, and washed and blocked with 0.5% normal goat 
serum in PBS (PBS-NGS).  Coverslips were then incubated in mouse monoclonal anti-
p53 DO-1 (Calbiochem, Billerica, MA, USA), rat monoclonal anti-VDR 9A7 (Sigma-
Aldrich, St. Louis, MO, USA) and rabbit polyclonal anti-p63 H129 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) primary antibodies for 1 hr at room temperature. 
Excess primary antibody was removed with three consecutive 5 min washes in PBS-NGS 
followed by incubation with AlexaFluor goat anti-rabbit 488 and goat anti-rat 568 
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antibodies at a dilution of 1:500 for 1 hr at room temperature. Excess secondary was 
removed with three consecutive 5 min washes in PBS-NGS and one wash in PBS prior to 
mounting with Vecta-Shield plus DAPI Mounting Media (Vector Laboratories, 
Burlingame, CA, USA). Cells were visualized and imaged using a Leica CTR 6000 
Microscope (Leica Microsystems, Wetzlar, Germany) and ImagePro 6.2 software (Media 
Cybernetics, Bethesda, MD). Mean fluorescent intensity was determined with the 
ImagePro 6.2 software after normalizing to background fluorescence.  At least 100 cells 
were measured for VDR and p63 staining intensity per condition for each experiment 
with n = 3 independent biological replicates. Student’s t-tests were used to determine 
significant differences relative to vehicle controls. 
E. Immunoprecipitation  
 Whole cell lysates were prepared by lysing cells in NP-40 lysis buffer (25 mM 
Tris, pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 1% Nonidet P-40, 1 mM 
sodium orthovanadate, 1mM NaF, 1 mM NaPP and 1 mM DTT) supplemented with 10% 
protease inhibitor cocktail (Sigma, St. Louis, MO). Cell lysates were subjected to four 
10-second pulses on a 60 Sonic Dismembranator (Thermo Fisher Scientific Inc., 
Fremont, CA, USA). Cell debris was removed by centrifuging the samples at 14,000 g for 
10 minutes. Total protein concentrations in the supernatant were determined by BCA 
assay (Thermo Fisher Scientific Inc., Fremont, CA, USA) and equivalent protein 
concentrations ranging for 500 μg to 1 mg were used for Immunoprecipitation (IP). 
Immunoprecipitates were pre-cleared with 10 μL of protein A agarose beads (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), followed by a 3-hour incubation with 30 μL 
protein A agarose beads and either monoclonal anti-myc-tag antibody (9B11) (Cell 
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Signaling Technology, Danvers, MA, USA) as a isotype control IP, or monoclonal anti-
p53 antibody (DO-1) (EMD Millipore, Billerica, MA, USA). Following incubation bead 
complexes were wash thrice with 0.5% Tween-20 in PBS. Protein complex formation 
was detected by immunoblot analysis as described below.    
F. Immunoblot analysis 
 Whole cell lysates were prepared by lysing the cells in phosphatase inhibitor 
containing buffer (50mM Tris-HCl pH 8, 120 mM NaCl, 5mM NaPPi, 10mM NaF, 30 
mM paranitrophenylphosphate, 1mM benzamidine, 0.1% NP-40, 1% Triton X-100 and 
0.2 PMSF, 100nM sodium orthovanadate) supplemented with protease inhibitor cocktail 
(Sigma, St. Louis, MO). Total protein concentrations were determined by BCA assay 
(Thermo Fisher Scientific Inc., Fremont, CA, USA). Equivalent concentration of proteins 
were resolved on 10% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) 
membranes. Proteins were detected using the following antibodies: mouse monoclonal 
anti-p53 DO-1 (EMD Millipore, Billerica, MA, USA), rabbit polyclonal anti-phospho-
Akt (Ser473), rabbit polyclonal anti-Akt, rabbit polyclonal anti-p38, rabbit polyclonal 
anti-phospho-p38 (Thr180/Tyr182), rabbit monoclonal anti-phospho-MAPKAPK-2 
(Thr222), rabbit polyclonal anti-MAPKAPK-2 (Cell Signaling Technology, Danvers, 
MA, USA), mouse monoclonal anti-VDR D-6, mouse monoclonal anti-pan-p63 4A4 and 
mouse monoclonal anti-β-actin and rabbit polyclonal anti-GFP (FL) antibodies (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA).  Anti-GFP (FL) antibody was obtained from 
the laboratory of Dr. Michael Leffak at Wright State University, Dayton, OH. 
Appropriate horseradish peroxidase-conjugated secondary antibodies in a dilution range 
from 1:2500 to 1:5000 (Promega, Madison, WI, USA) were used for chemiluminescence 
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detection with Western Lightning Plus chemiluminescent kit (Perkin Elmer, Waltham, 
MA, USA). Band intensities were normalized to -actin, and fold changes in protein 
expression were calculated relative to vehicle or non-silencing controls (NSC).  
G. Cell growth assays 
 Cells were seeded at 5000 cells per well in a 96-well flat bottom culture dish, and 
treated with 1 nM, 10 nM or 100 nM VD3 24 hour later. Proliferation was assessed using 
Promega CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) (Thermo 
Fisher Scientific Inc., Fremont, CA, USA) at various time points post-treatment 
according to established methods (Leonard et al., 2011). Student’s t-tests were used to 
determine significant changes in cell proliferation relative to vehicle controls from three 
independent biological replicates. Cell viability was also measured by trypan blue 
exclusion and carried out in triplicate per condition per day post VD3 treatment. 
H. Tissue Immunofluorescence Staining 
 Formalin fixed, paraffin-embedded human skin sections were stained for p63, and 
VDR as previously described (Kommagani et al., 2009; Leonard et al., 2011) with one 
modification. Briefly, the humans tissue were co-stained for p63 and VDR with two 
different antigen retrieval processes, a heat base antigen retrieval method was used for 
p63 followed by (Kommagani et al., 2009; Leonard et al., 2011) an acid antigen retrieval 
processes for VDR and finally neutralization with 0.1 M Borate Buffer pH 8.5 (Hill et al., 
2014). Human tissue samples consisted of normal skin (N=49), precursor to SCC (N=59) 
which included actinic keratosis (AK) N=22, acantholytic actinic keratosis (AA) N=6, 
acantholytic and hyperplastic actinic keratosis (AKAH) N=10, hyperplastic actinic 
keratosis (HA) N=15, squam in situ N=4 and bowenoid actinic keratosis (BA) N=2, SCC 
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(N=53) which included superficial squamous cell carcinoma (SSCC) N=13, squamous 
cell carcinoma with perineural invasion, squamous cell carcinoma (SCC) N=3, BCC 
(N=54) which included infiltrative basal cell carcinoma  (IBCC) N=4, nodular basal cell 
carcinoma (NBCC) N=29, nodular and infiltrative basal cell carcinoma (NIBCC) N=6 
and superficial basal cell carcinoma (SBCC) N=15. Tissues were imaged using a Leica 
CTR 6000 Microscope (Leica Microsystems, Wetzlar, Germany). Three pictures per 
tissue at sites that represents a constant staining for the tissue were taken on the Leica 
CTR 6000 Microscope. Three measurements, all the same size, of the mean fluorescence 
intensity were taken of the epidermal tissue or cancerous tissues for each picture. 
Average mean fluorescence intensity was calculated following normalization to 
background by using the ImagePro 6.2 software.  
I. Statistical analysis for stained tissue 
Adjusted mean MFI and standard error of mean (SEM) levels of p63 and VDR from 
normal skin samples, Basal cell carcinoma samples, Squamous cell carcinoma samples, 
and precursor to Squamous cell carcinoma samples were plotted. Repeated measures 
Analysis of Variance (ANOVA) tests were conducted to account for the correlation 
between repeated measurements (9 measurements per sample). A comparison of several 
covariance structures was performed to find the best covariance structure as determined 
using the Akaike Information Criterion (AIC) (Akaike, 1974).  Post-hoc multiple 
comparison procedures using Dunnett’s test were performed to compare between mean 
MFI values of p63 or VDR between control samples (i.e., normal skin samples) and all 
other carcinoma samples (Dunnett, 1955, 1980).  PROC MIXED procedure 
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(SAS/STAT®, Ver 9.3, SAS Institute Inc., Cary, NC) was used for analyses. Experiment 
wise error rates under 0.05 were considered statistically significant.  
J. Quantitative Reverse transcription PCR for gene expression 
Total RNA was extracted from human cells using the eZNA RNA isolation kit according 
to the manufacturer protocol (Omega Bio-Tek, Norcross, GA, USA). Total RNA 
extracted from the skin of VDR knockout mice and wild type littermates were provided 
by Dr. Glendon Zinser (University of Cincinnati) in full accordance with the Institutional 
Animal Care and Use Committee of the University of Cincinnati. A TaqMan reverse 
transcription kit (Life Technologies, Carlsbad, CA USA) was used to synthesize cDNA 
from 1g of total RNA. Quantitative real-time PCR analysis was performed as previously 
described using an Assay on Demand (AOD) specific for the genes of interest and 
normalized to endogenous GAPDH for human genes or to β-actin for murine genes of 
interest (Life Technologies, Carlsbad City, CA, USA) (Pfaffl, 2001; Kommagani et al., 
2009). Human AODs used were GAPDH (4325792), VDR (Hs0017213_ml), p53 
(Hs00153340_m1) and pan-p63 (Hs00978340_ml). Murine AODs used were pan p63 
(Mm00495788_m1), VDR (Mm00437297_m1) and β-actin (Mm00607939_s1). Each 
experiment had an n = 3 independent experiments. Student’s t-tests were used to 
determine significant difference relative to controls. 
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III. RESULTS 
A. VDR is essential for basal expression of Np63 
 To determine if VDR increases Np63 expression in vitro, I used several 
keratinocyte cell lines. HaCaT cells, the most commonly used spontaneously 
immortalized keratinocyte cells, were used in all experiments (Boukamp et al., 1990; 
Mueller et al., 2001). The HaCaT cell line closely resembles normal keratinocyte in 
growth and differentiation patterns (Mueller et al., 2001). Furthermore, the cell line does 
not contain any viral sequences that could introduce genomic instability, thus allowing 
them to remain non-tumorigenic over numerous passages (Mueller et al., 2001).  The 
HaCaT cell line contains two mutant alleles of p53 (H179Y and R282W) that are a result 
of UV irradiation and are thought to contribute to the spontaneous transformation 
(Mueller et al., 2001; Yang, D. et al., 2007; Li, X. et al., 2012) (Figure 3).  HaCaT II-4, a 
HaCaT clone, was produced by the addition of H-Ras to the HaCaT genome (Boukamp et 
al., 1990; Mueller et al., 2001) allowing the cells to become tumorigenic (Boukamp et 
al., 1990; Mueller et al., 2001). The HaCaT II-4 cell line was used in the experiments 
investigating the effect of VDR on Np63.  The A431-EGFR cell line is a squamous 
carcinoma cell line which overexpresses epidermal growth factor receptor (EGFR) 
(Yamamoto et al., 1986). A431 cells express two different Gain-of-function mutant 
alleles of p53 (R273H and R273C) (Somers et al., 1992; Mueller et al., 2001; Rantanen 
et al., 2002; Yang, D. et al., 2007; Li, X. et al., 2012) (Figure 3). The A431 cell line was 
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originally derived from the squamous cell carcinoma lesion of an 85 year old woman 
(Thomasen et al., 2015). This cell line was used to validate the effects of VDR or VD3 on 
Np63 expression seen in the keratinoycte cell lines thereby acting as a squamous cell 
carcinoma model. Finally, to determine the effects of VDR on Np63 in cells with wild 
type p53, I also used the neonatal human keratinocyte cell line (nHEK) isolated from the 
foreskin of newborn infants (Rheinwald & Green, 1977).  
 Previous studies in our laboratory have shown that VDR is a direct target of 
Np63. (Kommagani et al., 2006; Kommagani et al., 2009).  Unfortunately, no studies 
to date have examined whether VDR can up-regulate Np63.  Since, both VDR and 
p63 are important in skin development, it is likely that both might contribute to the onset 
and progression of NMSC. Thus, it is imperative to understand the mechanism by which 
both proteins regulate each other and elicit downstream effects in cancer. The VDR 
ligand, VD3, enhances survival and proliferation in keratinocytes (Bollag et al., 1995; 
Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008; Kovalenko et al., 2011), while 
Np63 is plays a major role in maintaining the proliferative capacity of basal layer 
keratinocytes (Mills et al., 1999).  Since both Np63 and VDR/VD3 can increase 
keratinocyte proliferation, I first examined if VDR mediates keratinocyte proliferation by 
regulating Np63 expression. Previously, immunoblot analysis showed that Np63 is 
the only detectable p63 isoform expressed in HaCaT and A431 cells (Kommagani et al., 
2006; Kommagani et al., 2009). To determine if VDR positively regulates the expression 
of Np63, I silenced VDR (siVDR) in two keratinocyte cell lines (HaCaT and HaCaT 
II-4) and examined Np63 expression at both the protein and transcript levels. To 
ensure that any change in Np63 observed upon loss of VDR was not an artifact of 
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transformation or dependent on the p53 status, I also silenced VDR in primary nHEK, 
which express wild-type p53. HaCaT, HaCaT II-4 and primary keratinocytes cells 
transfected with siRNA against VDR showed a significant reduction in VDR transcript 
and protein levels (Figure 8A and 8B), thus confirming siRNA function. Knockdown of 
VDR in HaCaT, HaCaT II-4 and primary keratinocytes led to a concomitant reduction in 
Np63 transcript and protein expression (Figure 8). Furthermore, when examining the 
effects of loss of VDR in the squamous cell carcinoma cell line A431, I observed a 
similar reduction in Np63 protein level as seen in the transformed and primary 
keratinocyte cell lines (Figure 9). To confirm that VDR positively regulates Np63 
expression in vivo, total RNA extracts from the skin of VDR knockout (KO) mice and 
wild type littermates were analyzed by RT-PCR. Complete ablation of VDR significantly 
reduced the transcript levels of p63 in the skin of VDR KO mice compared to wild type 
controls (Figure 8C). Taken together, this data demonstrates that VDR positively 
regulates Np63 expression in vitro and in vivo. In silico analysis of Chip-Seq data 
revealed three VDREs upstream of the p63 gene and one VDRE in the 3’ untranslated 
region (UTR) of p63 (Tuoresmaki et al., 2014), suggesting that it is likely p63 is a direct 
transcriptional target of VDR. 
B. Np63 protein levels increased following treatment with low dose VD3.  
VDR functions in a ligand-dependent and ligand-independent manner in epidermal 
keratinocytes (Haussler et al., 2011; Haussler et al., 2012). The ligand for VDR, VD3, is 
synthesized in the skin by a reaction that requires UVB energy to convert 7-
dehydrocolestoral to the biologically active form 1, 25-dihydroxyvitamin D3 called   
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Figure 8: VDR is critical for basal expression of Np63. (A) HaCaT (left panel), 
HaCaT II-4 (right panel) and (B) NHEK cells were transfected with non-silencing control 
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(NSC) or siRNA specific for VDR. Changes in mRNA levels and protein expression of 
p63 and VDR were measured by qRT-PCR (*=p values ≤ 0.05) and immunoblot 
analyses, respectively. The fold-change in protein levels, relative to NSC transfected 
cells, is listed above each band. (C) Total RNA extracted from skin of wild type or VDR 
knockout (KO) mice was subjected to qRT-PCR to measure the change in VDR and p63 
transcript levels. *=p values ≤ 0.05. (Hill et al., 2015). 
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Figure 9: Loss of VDR reduced Np63 protein expression in A431 cells. A431 cells 
were transfected with non-silencing control (NSC) or siRNA against VDR. The change in 
p63 and VDR was measured by immunoblot analysis. The fold-change in protein levels, 
relative to NSC transfected cells, is listed above each band. (Hill et al., 2015). 
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calcitrol.  UV radiation is also the most common cause of NMSC, and NMSCs frequently 
overexpress Np63. Thus, it is important to determine if VD3 contributes to VDR-
mediated regulation of Np63 and what phenotypic changes occur due to alteration in 
Np63 expression. Having demonstrated that VDR is important for maintaining basal 
expression of Np63, I next wanted to determine whether VDR modulates Np63 
expression in a ligand-dependent or -independent manner. First, I examined the effects of 
increasing doses of VD3 on Np63 expression and observed a dose dependent increase 
in Np63 levels up to 10 nM, while 50 nM and 100 nM VD3 showed a decline in 
Np63 expression relative to cells treated with 10 nM VD3 (Figure 10). Furthermore, 
VDR protein expression increased in a dose dependent manner following VD3 treatment 
(Figure 10). Therefore, I utilized 10 nM and 100 nM VD3 in subsequent experiments to 
evaluate any changes in Np63 expression induced by VD3 in HaCaT, HaCaT II-4 and 
A431 cells. Furthermore, the 10 nM dose of VD3 is more in line with VD3 deficiency and 
the 100 nM dose in similar to a dose that is consider cancer preventive (Cannell & Hollis, 
2008; Ross et al., 2011) in humans. While treatment with low dose VD3 increased 
Np63 protein levels in HaCaT, HaCaT II-4 and A431 cells (Figure 11 and Figure 12), 
high doses of VD3 did not significantly affect Np63 protein levels relative to vehicle 
controls at 24 hours post VD3 treatment (Figure 11). As shown in Figure 11 and 
consistent with Figure 10, VDR levels increased in a dose dependent manner following 
24 hours of VD3 treatment.  To further confirm VD3 mediated increases in Np63, I 
measured the changes in Np63 expression via immunofluorescence. Consistent with 
immunoblot analysis, immunofluorescent staining of p63 and VDR in cells treated with 
10 nM of VD3 clearly showed an increase in   
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Figure 10: VD3-mediated increase in Np63 protein expression peaks at the 10 nM 
dose of VD3. HaCaT cells were treated with vehicle, 1 nM VD3, 5 nM VD3 10 nM VD3, 
50 nM VD3 or 100 nM VD3 for 24 hours then subjected to immunoblot analysis for 
Np63, VDR and β-actin. The fold-change in protein levels, relative to vehicle treated 
cells, is listed below each band. (Hill et al., 2015). 
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Figure 11: VD3 dosage differentially affects Np63. HaCaT (A) and HaCaT II-4 (B) 
cells were treated with vehicle, 10 nM VD3 or 100 nM VD3 for 24 hours then subjected to 
immunoblot analysis for Np63, VDR and β-actin. The fold-change in protein levels, 
relative to vehicle treated cells, is listed above each band. (Hill et al., 2015). 
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Figure 12: VD3 dosage differentially affects Np63 expression in A431 cells.  A431 
cells were treated with vehicle, 10 nM VD3 or 100 nM VD3 for 48 hours then subjected to 
immunoblot analysis for Np63, VDR and β-actin. The fold-change in protein levels, 
relative to vehicle treated cells, is listed above each band. (Hill et al., 2015). 
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Figure 13: Low dose VD3 increases Np63 expression. Top panel: HaCaT and 
HaCaT II-4 were treated with vehicle, 10 nM VD3 or 100 nM VD3 overnight followed by 
detection of ΔNp63α and VDR by immunofluorescence. Bottom panel: average mean 
intensity of immunofluorescence staining for ΔNp63α and VDR in HaCaT and HaCaT II-
4.  Error bars represent standard error of the mean. *=p values ≤ 0.05 compared to 
vehicle control cells. Each sample consists of a 100 counted cells per experiment. (Hill et 
al., 2015). 
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Np63 expression compared to 100 nM of VD3 or vehicle treated cells (Figure 13). 
These results establish that only low doses of VD3 lead to increased Np63 protein 
levels. Therefore, this data indicates that changes in VD3 levels following UV radiation 
could potentially be one factor that leads to increased Np63 expression in NMSC.  
C. VD3 increases Np63 transcript level 
 Classical VD3 signaling involves the transcription of VDR target genes induced 
by binding of VD3 (Deeb et al., 2007; Haussler et al., 2011). Thus far, I have shown that 
VDR positively regulates Np63 and that low dose VD3 increases Np63 protein 
expression. In order to understand the mechanism behind VD3-mediated regulation of 
Np63, I next examined whether VD3 treatment affects Np63 transcription. To test 
whether VD3 increases Np63 transcript, I examined the transcripts levels of p63, VDR 
and CYP24A in HaCaT (Figure 14A) and HaCaT II-4 (Figure 14B) cells following 
treatment with 10 nM or 100 nM VD3 for 24 hours. As a positive control, I measured 
transcript levels of a known target of VD3, CYP24A.  Both concentrations of VD3 led to a 
modest but significant increase in p63 transcript levels when compared to vehicle treated 
controls. VD3 did not significantly affect VDR transcript levels at 100 nM VD3 in HaCaT 
and at both doses tested in HaCaT II-4.  As expected, there was a dose dependent 
increase in the CYP24A transcript levels following VD3 treatment. Taken together, both 
100 nM and 10 nM doses of VD3 modestly increased p63 transcript levels, indicating that 
VD3 can potentially increase Np63 transcript levels. Unfortunately, I did not observe a 
significant increase in Np63 protein expression with 100 nM VD3, which may point to 
alternative mechanisms by which low dose VD3 increases Np63 such as kinase 
activation leading to increased Np63 protein stabilization. 
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Figure 14: VD3 increases Np63 transcript levels. (A) HaCaT and (B) HaCaT II-4 
cells were treated with vehicle, 10 nM VD3 or 100 nM VD3 for 24 hours. Transcript 
levels of p63 (top panel), VDR (middle panel) and CYP24A (bottom panel) were 
analyzed by TaqMan based qRT-PCR (*=p values ≤ 0.05). (Hill et al., 2015). 
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D. VD3 mediated induction of Np63 occurs via p38 and Akt activation.  
 Since the effects of VD3 on the Np63 transcript level did not mimic the 
observed changes in protein expression, I decided to examine alternative mechanism by 
which low dose VD3 could lead to increased Np63 protein levels. Previous studies 
have shown that VD3 treatment increases Akt activation, particularly with a 10 nM dose 
of VD3 (Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008). Furthermore, low doses of 
VD3 are not considered to be cancer preventive, but could potentially contribute to cancer 
onset and progression (Garland et al., 2009; Ness et al., 2015). The Akt pathway, 
commonly elevated in cancer, has been shown to increase Np63 protein expression 
(Ogawa et al., 2008). Thus, I investigated whether activated Akt was required for the 
increased Np63 protein levels observed upon low dose VD3 treatment.  I measured 
Akt activation after treatment with VD3 using an antibody directed against 
phosphorylated serine 473 of Akt (pAkt), indicative of fully activated Akt. I observed 
that Akt activation by low dose VD3 occurred within five minutes. This activation of Akt 
preceded the increase in Np63 protein levels, which occurred within 2 hours (Figure 
15). To show that increased Np63 levels and cell growth observed upon low dose VD3 
treatment is as a result of activated Akt, I next examined the effect of VD3 on Np63 
levels following inhibition of Akt activity with a small molecule allosteric Akt-specific 
inhibitor, MK2206. MK2206 prevents Akt binding PIP3 via its pleckstrin homology 
domain preventing Akt phosphorylation at T308 and S473 and thereby Akt activation 
(Yap et al., 2011). Inhibition of Akt activity reduced Np63 levels in all conditions 
(Figure 16).  However, low dose VD3 treatment in conjunction with MK2206 still 
exhibited  
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Figure 15: VD3-mediated increased Np63 levels follows Akt activation. HaCaT 
cells were treated with 10 nM or 100 nM VD3 and harvested at different time points as 
indicated. Whole cell lysates were subjected to immunoblot analysis for p63, pAkt, Akt 
and β-actin. (Hill et al., 2015). 
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Figure 16: VD3 up-regulates Np63 levels partly through Akt activation. HaCaT 
cells were pretreated with 10 M of the Akt inhibitor MK2206 or DMSO control for 1 
hour followed by treatment with either vehicle, 10 nM VD3 or 100 nM VD3 in 
combination with DMSO or MK2206 for 24 hours. Whole cell lysates were subjected to 
immunoblot analysis for the indicated proteins. The fold-change in protein levels for 
Np63, relative to DMSO/vehicle control treated cells is listed below each band. (Hill 
et al., 2015). 
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slightly higher levels Np63 when compared to cells treated with  MK2206 and vehicle 
(Figure 16). Together this data indicates that Akt only partially regulates Np63 protein 
expression in response to VD3.   
 Since Akt only partially regulates Np63 following VD3 treatment, I next 
examined the role of p38 Mitogen activated protein kinase (MAPK) signaling pathway in  
 VD3 mediated increases in Np63 levels. In addition to VD3 treatment, a variety of 
other stimuli such as stress, growth factors and cytokines have been shown to activate 
p38 MAPK (Buitrago, C. G. et al., 2006; Buitrago, C. & Boland, 2010). Activated p38 
MAPK was shown to increase ΔNp63α levels and cell proliferation in limbal epithelial 
cells (Cheng et al., 2009). Furthermore, p38 MAPK down-regulates cell cycle 
progression and proliferation through the phosphorylation of downstream transcription 
factors, such as p53, or kinases such as MAPK-activated protein kinase 2 (MAPKAPK-2 
or MK2). MAPKAPK-2 is a well-known p38 MAPK target and is routinely used to 
confirm p38 MAPK activation in response to many stimuli. Originally, p38 MAPK was 
thought to inhibit proliferation, but studies in muscle cells support the idea that p38 
MAPK can also promote cell proliferation (Zarubin & Han, 2005; Buitrago, C. G. et al., 
2006; Buitrago, C. & Boland, 2010; Cuadrado & Nebreda, 2010). This suggests that that 
activation of p38 MAPK following VD3 treatment could increase Np63 protein levels, 
thereby increasing keratinocyte proliferation. Therefore, I wanted to determine if p38 
activation upon VD3 treatment was required to increase Np63 protein levels. To assess 
p38 MAPK activation by VD3 in HaCaT cells following treatment with 10 nM and 100 
nM of VD3, I monitored phosphorylation of p38 MAPK and its downstream target 
MAPKAPK-2 at various time points post-treatment. VD3 induced the phosphorylation of  
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Figure 17: VD3 increases p38 activation prior to increasing Np63 levels. HaCaT 
cells were treated with 10 nM or 100 nM VD3 and harvested at different time points as 
indicated. Whole cell lysates were subjected to immunoblot analysis for p-p38, p63, 
pMAPKAPK-2, p38 and β-actin. (Hill et al., 2015). 
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both p38 MAPK and MAPKAPK-2 within five minutes of VD3 treatment and this 
activation persisted longer following treatment with 10 nM VD3 when compared to 100 
nM VD3 treatment (Figure 17). Consistent with Figure 15, I observed an increase in 
Np63 protein levels following kinase activation in response to treatment with 10 nM 
VD3 (Figure 17). To confirm that VD3 increased Np63 protein levels via p38 MAPK 
activation, I next examined whether pre-treatment with the p38 MAPK inhibitors 
SB202190 or BIRB-796 prior to VD3 treatment would lead to a decrease in Np63 
protein levels. The p38α and p38β inhibitor, SB202190, inhibits the active form of p38 
MAPK by competing with ATP for the ATP binding pocket (Young, P. R. et al., 1997; 
Frantz et al., 1998).  The pan-p38 inhibitor, BIRB-796, forms a hydrogen bond between 
the morpholine oxygen and the ATP binding domain (Pargellis et al., 2002). Use of the 
SB202190 p38 MAPK inhibitor lead to a reduction in the activation of the p38 MAPK 
downstream target MAPKAPK-2 measured by a decrease in the upper band indicative of 
phosphorylation (Figure 18). Furthermore, inhibition of p38 with BIRB-796 led to a 
reduction in p-p38 MAPK levels and subsequently a reduction in the activation of 
MAPKAPK-2 (Figure 19). Inhibition of p38 activity by both SB202190 and BIRB-796 
led to a reduction in the Np63 protein levels as shown in Figure 18 and Figure 19, 
respectively. Furthermore, low dose VD3 was unable to rescue ΔNp63α levels when p38 
MAPK activation was inhibited (Figure 18 and Figure 19), indicating that increased 
Np63 levels in response to low doses of VD3 occur via p38 MAPK activation.   
E. Effects of VD3 treatment on cell proliferation correlates with Np63 
protein levels. 
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Figure 18: Inhibition of p38 activation with the p38α/β inhibitor SB202190 reduced 
VD3-mediated increase in Np63. HaCaT cells were pretreated with 15 M 
SB202190 or DMSO control for 1 hour followed by treatment with either vehicle, 10 nM 
VD3 or 100 nM VD3 in combination with DMSO or SB202190 for 24 hours. Whole cell 
lysates were subjected to immunoblot analysis for the indicated proteins. The fold-change 
in protein levels for Np63, relative to DMSO-vehicle treated cells is listed below each 
band. Arrow indicate the location of pMAPKAPK-2. (Hill et al., 2015). 
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Figure 19: Inhibition of p38 activation with the pan-p38 inhibitor BIRB-796 
reduced VD3-mediated increase in Np63. HaCaT cells were pretreated with 1 M 
BIRB-796 or DMSO control for 2 hours followed by treatment with either vehicle, 10 
nM VD3 or 100 nM VD3 in combination with DMSO or BIRB-796 for 24 hours. Whole 
cell lysates were subjected to immunoblot analysis for the indicated proteins. The fold-
change in protein levels for Np63, relative to DMSO-vehicle treated cells is listed 
below each band. (Hill et al., 2015). 
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 Previous studies have shown a correlation between increased Np63 expression 
and cell proliferation in squamous cell carcinomas (Reis-Filho et al., 2002; Sniezek et al., 
2004; Lo Muzio et al., 2005). Furthermore, Np63 is expressed predominantly in the 
proliferative basal level of epithelial tissues. Since low dose VD3 increased Np63 
levels (Figures 10-14), I examined whether low dose VD3 treatment also led to increased 
keratinocyte proliferation, as Np63 has been showed to increase proliferation (Danilov 
et al., 2011). To assess this, I monitored cell proliferation by MTS assay and trypan blue 
exclusion at various time points following treatment of cells with VD3. As seen in Figure 
20, 10 nM VD3 significantly increased proliferation in both HaCaT and HaCaT II-4 cells, 
while 100 nM VD3 reduced cell proliferation when compared to vehicle treated controls. 
I further confirmed dose effect of VD3 on increased cell proliferation by counting trypan 
blue stained HaCaT and HaCaT II-4 cells treated with 1, 10, or 100 nM doses of VD3 as 
shown in Figure 21A. Consistent with results obtained using MTS assay (Figure 20 and 
Figure 21A), live cell number by trypan blue exclusion confirmed an increased cell 
number with 1 nM and 10nM of VD3 while 100 nM of VD3 did not significantly alter cell 
number when compared to vehicle treated cells (Figure 21B).  Together our results 
demonstrate that VD3 affects cell proliferation in a dose-dependent manner and 
correlating with the effects of VD3 on Np63 levels (Figure 11). 
F. VDR and p63 are both play a major role in VD3-mediated cell proliferation 
VD3 was previously shown to function independently of its receptor, VDR (Wali 
et al., 2003) thus bringing to the light the possibility that VDR may not be necessary for 
VD3 mediated increase in keratinocyte proliferation which correlates with VD3 mediated 
increase Np63 protein levels. Therefore, I wanted to determine if VD3 mediated  
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Figure 20: VD3 dosage differentially affects cell proliferation. HaCaT (A) and HaCaT 
II-4 (B) cells were treated with vehicle, 10 nM VD3 or 100 nM VD3 for 8, 24 and 48 
hours and cell proliferation was measured by MTS cell titer assay. The Y-axis indicates 
fold change compared to vehicle treated cells. Error bars represent standard deviation 
from the mean. *=p values ≤ 0.05 compared to vehicle control cells at 8 hours. (Hill et 
al., 2015).  
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Figure 21: Low dose VD3 increases keratinocyte proliferation. (A) HaCaT and HaCaT 
II-4 cells were treated with vehicle, 1 nM VD3, 10 nM VD3, or 100 nM VD3 for 8, 24, 48 
and 72 hours then cell proliferation was measured post each VD3 treatment by MTS 
assay. (B) HaCaT and HaCaT II-4 cells were treated with vehicle, 1 nM VD3, 10 nM 
VD3, or 100 nM VD3 for 24, 48 and 72 hours followed by cell proliferation measurement 
by trypan blue cell exclusion. Error bars represent standard deviation from the mean. 
(Hill et al., 2015). 
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effects on keratinocyte proliferation are dependent on VDR expression. To this end, I 
examined the effects of VDR knockdown on cell proliferation following VD3 treatment. 
HaCaT and HaCaT II-4 cells were transfected with non-silencing control siRNA or VDR 
specific siRNA followed by treatment with VD3. As expected, low dose VD3 increased 
HaCaT and HaCaT II-4 cell proliferation when compared to vehicle control treated cells 
that were transfected with non-silencing control siRNA (Figure 22). Knockdown of VDR 
dramatically reduced cell proliferation in both HaCaT and HaCaT II-4 cells, regardless of 
VD3 dose when compared to control siRNA transfected cells (Figure 22A and 22B top 
panel). Immunoblot analyses of cells treated with VD3 following knockdown of VDR 
confirmed VDR loss following silencing with siRNA against VDR (Figure 22A and 22B 
bottom panel). Furthermore, loss of VDR in VD3 treated cells lead to a reduction in the 
basal Np63 levels as well as significantly reduced 10 nM VD3 mediated induction of 
Np63 protein when compared to control cells (Figure 22A and 22B bottom panel). 
Taken together this data shows that VDR plays an important role VD3 mediated increase 
in Np63 and keratinocyte proliferation, indicating that the regulation of Np63 and 
keratinocyte proliferation is a VDR ligand dependent function. Since Np63 contributes 
to increased proliferation and its expression is dependent on VDR, I next wanted to 
confirm if the decreased Np63 expression observed after knockdown of VDR was 
responsible for the concomitant reduction in proliferation. Therefore, p63 was silenced 
with siRNA specific to p63 prior to VD3 treatment of HaCaT and HaCaT II-4 cells. As 
expected, low dose VD3 led to a significant increase in keratinocyte proliferation when 
compared to vehicle or 100 nM VD3 treated cells transfected with non-silencing control  
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Figure 22: VDR is important for VD3-mediated cell proliferation. HaCaT (A) and 
HaCaT II-4 (B) cells were transfected with non-silencing control (NSC) or siVDR 
followed by treatment with vehicle control, 10 nM or 100 nM VD3 for 8, 24 and 48 hours 
as indicated. Cell proliferation was measured by MTS cell titer assay. Y-axis represents 
fold change compared to NSC transfected vehicle treated cells. Error bars represent 
standard deviation from the mean. *=p values ≤ 0.05 compared to NSC vehicle control 
cells at 8 hours. Confirmation of silencing was measured by Western blot following VD3 
treatment (lower panels). (Hill et al., 2015). 
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siRNA (Figure 23A and 23B top panel). Silencing p63 dramatically reduced cell 
proliferation in cells treated with vehicle, 10 nM or 100 nM of VD3 compared to cells 
transfected with control siRNA and VD3. This shows that Np63 is important for VD3 
mediated increases in keratinocyte cell proliferation (Figure 23A and 23B top panel). 
Previously, our laboratory showed that Np63 positively regulates VDR transcription 
and protein expression. Here, I wanted to determine the effect of Np63 knockdown on 
VD3-mediated increase in VDR. Immunoblot analysis for VDR following p63 
knockdown and in HaCaT and HaCaT II-4 cells treated with VD3 demonstrated a 
reduction in the VD3-mediated increases in VDR protein levels (Figure 23A and 23B 
bottom panel). To confirm that the change in cell proliferation was not an artifact of the 
MTS assay, I also measured the change in cell viability following VD3 treatment of 
HaCaT and HaCaT II-4 that were transfected with siRNA against p63 or VDR by trypan 
blue exclusion. Consistent with MTS assay, cells transfected with control siRNA showed 
a dramatic increase in cell proliferation in response to low dose VD3 treatment (Figure 
24). As shown in Figure 24, I observed that loss of p63 or VDR led to a reduction in 
VD3-mediated increase in keratinocyte proliferation by trypan blue cell counting further 
confirming that both p63 and VDR are important for VD3-mediated increase in cell 
proliferation. 
G. VD3 mediated increase keratinocyte proliferation involves p38 and Akt 
activation.  
 Akt activation was partly involved in VD3 mediated increase in Np63 
expression. Therefore, I decided to examine the combined effects of loss of VDR 
expression and inhibition of Akt on keratinocyte proliferation following VD3 treatment.  
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Figure 23: Np63 is important for VD3-mediated cell proliferation. HaCaT and 
HaCaT II-4 cells were transfected with non-silencing control (NSC) or sip63 followed by 
treatment with vehicle control, 10 nM or 100 nM VD3 for 8, 24 and 48 hours as indicated. 
Cell proliferation was measured by MTS cell titer assay. Y-axis represents fold change 
compared to NSC transfected vehicle treated cells. Error bars represent standard 
deviation from the mean. *=p values ≤ 0.05 compared to NSC vehicle control cells at 8 
hours.  Confirmation of silencing was measured by Western blot following VD3 
treatment (lower panels). (Hill et al., 2015). 
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Figure 24: Confirmation that VDR and Np63 play a role in VD3-mediated 
increase in cell proliferation. HaCaT (A) and HaCaT II-4 (B) cells were transfected 
with siRNA against p63 or VDR followed by treatment with vehicle control or VD3 at 10 
nM or 100 nM for 24 and 48 hours. Cell viability was measured by trypan blue cell 
exclusion. Error bars represent standard deviation from the mean. *=p values ≤ 0.05 
compared to NSC vehicle control cells at 24 hours.  (Hill et al., 2015). 
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To this end, I measured changes in proliferation in HaCaT cells pre-treated with MK2206 
(inhibitor of Akt activation) for 1 hour in presence or absence of VDR followed by VD3 
treatment in the presence or absence of MK2206 for 24 hours.  Loss of VDR alone or 
inhibition of Akt alone reduced HaCaT proliferation to similar levels regardless of VD3 
dose (Figure 25). Interestingly, loss of VDR combined with Akt inhibition led to a further 
reduction in cell proliferation. This data is consistent with the effect of loss of Akt 
activation on Np63 protein and suggests that increased keratinocyte proliferation 
following low dose VD3 treatment is likely only partially occurring via VD3 mediated 
activation of Akt.  
 Having shown that p38 MAPK is involved in VD3-mediated increase in Np63, 
I next wanted to show a correlation between the effects of p38 MAPK on Np63 and 
keratinocyte proliferation following VD3 treatment in the absence or presence of VDR. 
Therefore, I studied the effects of SB202190 (p38 MAPK inhibitor) pre-treatment on cell 
proliferation in presence or absence of VDR following VD3 treatment in HaCaT cells. As 
expected in cells transfected with non-silencing control siRNA, there was an increase in 
HaCaT proliferation following low dose VD3 treatment compared to control cells. 
Inhibition of p38 MAPK with SB202190 led to a reduction in cell proliferation in cells 
treated with 10 nM VD3 compared to vehicle controls and high dose VD3-treated cells 
(Figure 26). Loss of VDR alone or in combination with p38 MAPK inhibition with 
SB202190 reduced keratinocyte proliferation to similar levels regardless of VD3 
treatment (Figure 26).  This data indicates that p38 MAPK plays a role in VD3-mediated 
increases in keratinocyte proliferation in the presence of VDR.  
 To further confirm p38 MAPK is involved in VD3-mediated increase in Np63  
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Figure 25: VD3 up-regulates keratinocyte proliferation in the presence of VDR 
partly through Akt activation. HaCaT cells were transfected with non-silencing control 
(NSC) or siRNA against VDR. Cells were incubated for 1 hour in media containing 10 
M Akt inhibitor MK2206 or DMSO control prior to treatment with the indicated doses 
of VD3 or vehicle for 24 hours and MK2206 or DMSO. Cell proliferation was measured 
24 hours post VD3 treatment by MTS assay. Error bars represent standard deviation from 
the mean. *=p values ≤ 0.05 compared to NSC/DMSO/vehicle control cells. (Hill et al., 
2015). 
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Figure 26: Loss of VDR and inhibition of p38 activation with the p38α/β inhibitor 
SB202190 further reduced VD3-mediated increase in keratinocyte proliferation. 
HaCaT cells were transfected with non-silencing control (NSC) or siRNA against VDR. 
Cells were pretreated with 15 M SB202190 or DMSO control for 1 hour prior to 
replacing media with fresh SB202190 and either vehicle, 10 nM VD3 or 100 nM VD3 for 
24 hours. Cell proliferation was measured 24 hours post VD3 treatment by MTS assay. 
Error bars represent standard deviation from the mean. *=p values ≤ 0.05 compared to 
NSC/DMSO/vehicle control cells. (Hill et al., 2015). 
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and thereby keratinocyte proliferation; I examined the effects of a second p38 MAPK 
inhibitor (BIRB-796) on keratinocyte proliferation. To this end, I measured changes in 
proliferation via MTS assay following the inhibition of p38 activation with BRIB-796 in 
HaCaT cells in the presence or absence of VDR knockdown that were treated with 
vehicle, 10 nM or 100 nM VD3. As expected, low dose VD3 increased keratinocyte 
proliferation in cells transfected with non-silencing control siRNA that were treated with 
VD3 (Figure 27). Consistent with the SB202190 p38 MAPK inhibitor, inhibition of p38 
MAPK with BRIB-796 led to a reduction in cell proliferation of cells treated with 10 nM 
VD3 compared to controls treated with vehicle or high dose VD3 (Figure 27). Inhibition 
of p38 MAPK with BRIB-796 alone or in combination with loss of VDR alone reduced 
keratinocyte proliferation to similar levels regardless of VD3 treatment (Figure 27).  
Taken together, these data indicate that p38 MAPK in the presence of VDR is important 
for low dose VD3-mediated increases in ΔNp63α protein levels, which correlates with 
VD3-mediated effects on keratinocyte proliferation. 
H. Np63 rescues VD3-mediated increase in proliferation following loss of VDR. 
The data presented thus far shows a correlation between VD3-mediated effects on 
ΔNp63α expression and keratinocyte proliferation in presence of VDR.  Next, I wanted to 
confirm that increased cell proliferation following low dose VD3 treatment was dependent 
on VDR/VD3 mediated regulation of Np63 expression. Therefore, I generated HaCaT 
stable cell lines expressing Np63 (HaCaT-Np63α) or eGFP (HaCaT-eGFP), the latter 
used as a control. Stable expression of Np63 and GFP by western blot analysis, 
showed that HaCaT-Np63 cells expressed increased levels of Np63 relative to 
HaCaT-eGFP controls (Figure 28A). Furthermore, only the HaCaT-eGFP cells expressed  
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Figure 27: Loss of VDR and inhibition of p38 activation with the pan-p38 inhibitor 
BIRB-796 further reduced VD3-mediated increase in keratinocyte proliferation. 
HaCaT cells were transfected with non-silencing control (NSC) or siRNA against VDR. 
Cells were pretreated with 1 M BIRB-796 or DMSO control for 2 hours prior to 
replacing media with fresh BIRB-796 or DMSO and either vehicle, 10 nM VD3 or 100 
nM VD3 for 24 hours. Cell proliferation was measured 24 hours post VD3 treatment by 
MTS assay. Error bars represent standard deviation from the mean. *=p values ≤ 0.05 
compared to NSC/DMSO/vehicle control cells. (Hill et al., 2015). 
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GFP protein (Figure 28A). Following confirmation of GFP and Np63 overexpression, 
HaCaT-eGFP and HaCaT-Np63 were transfected with siRNA against VDR or non- 
silencing control (NSC) siRNA followed by treatment with vehicle control, 10 nM or 100 
nM VD3. At 24 hours post-VD3 treatment, cell viability was assessed by trypan blue 
exclusion to quantify changes in proliferation. As shown in Figure 28B, low dose 10 nM 
VD3 led to an increased cell number in both HaCaT-eGFP and HaCaT-Np63 cells 
transfected with NSC compared to vehicle or 100 nM VD3 treated cells. Consistent with 
data presented earlier (Figure 22), loss of VDR led to a reduction in HaCaT-eGFP cell 
number regardless of VD3 dose (Figure 28B). Importantly, Np63 rescued the effects of 
VDR knockdown in HaCaT-Np63 cells pre-treated with 10 nM VD3 (Figure 28B). 
Taken together, our results confirm that increased keratinocyte proliferation following 
treatment with low dose VD3 is dependent on VDR-mediated regulation of Np63 
expression. 
I. VDR and p63 expression are increased in non-melanoma skin cancer. 
 Np63 increases keratinocyte proliferation and has been shown to play a role in 
maintaining the proliferative capacity of basal keratinocytes in vivo (Koster et al., 2004; 
Carroll et al., 2006; Leonard et al., 2011; Romano & Sinha, 2011; Jeng-Yuan Yao, 2012; 
Orzol et al., 2012).   Previous work from our laboratory has shown that ΔNp63α 
positively regulates VDR. In this study, I have shown that VDR positively regulates 
ΔNp63α expression. Since VDR up-regulates ΔNp63α and ΔNp63α is overexpressed in a 
number of non-melanoma skin cancers (NMSC), I wanted to show that there is a 
correlation between increased ΔNp63α levels, VDR levels in NMSC. Therefore, I 
examined the expression levels of p63 and VDR in paraffin embedded skin   
 70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Np63 rescues reduction in VD3-mediated cell proliferation following 
loss of VDR. A) The expression of eGFP and Np63 were confirmed in HaCaT-eGFP 
and HaCaT-Np63 stable cells via immunoblot analysis. B) HaCaT-eGFP and HaCaT-
Np63 stable pools were transfected with non-silencing control (NSC) or siVDR 
followed by treatment with vehicle control, 10 nM or 100 nM VD3 for 24 hours. Cell 
viability was measured following VD3 treatment by trypan blue cell exclusion. Error bars 
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represent standard deviation from the mean. *=p values ≤ 0.05 compared to vehicle 
control EGFP expressing HaCaT cells. #=p values ≤ 0.05 compared to 10 nM EGFP 
expressing HaCaT cells. (Hill et al., 2015). 
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samples from individuals with normal skin (N=49) and patients with the precursors to 
SCC (N=59), squamous cell carcinoma (SCC) (N=53) and basal cell carcinomas (BCC) 
(N=54) by immunofluorescence to determine if there is a correlation between p63 and 
VDR expression levels. I observed higher levels of both p63 and VDR in BCC followed 
by SCC and the precursors to SCC when compared to normal non-cancerous skin as 
shown in representative images (Figure 29). Following quantitation I showed that the 
levels of both p63 and VDR were significantly highest in BCC followed by SCC and 
precursors to SCC (Figure 30). Furthermore, linear regression analysis shows that 
increased p63 expression correlates with an increase in VDR expression in these samples 
(Figure 31), indicating that there is a correlation between increased p63 and VDR levels 
in NMSC.  
 In order to further understand the relationship between p63 and VDR in non-
melanoma skin cancers, I re-analyzed the expression of p63 and VDR levels based on the 
different sub-types of precursors to SCC, SCC and BCC. As shown in Figure 33, mean 
fluorescent intensity measurements showed increased expression of p63 in three of the 
six precursors to invasive SCC; Actinic Keratosis Acantholytic Hyperplastic, 
Hyperplastic Actinic Keratosis and Squamous cell carcinoma in situ, when compared to 
normal skin (Figure 32 and Figure 33). Similar to p63, VDR also showed increased 
expression in three of the six subtypes; Actinic Keratosis, Hyperplastic Actinic Keratosis 
and Squamous cell carcinoma, but only Hyperplastic Actinic Keratosis and Squamous 
cell carcinoma displayed significant increases in both VDR and p63 expression (Figure 
32 and Figure 33). Moreover, examination of the expression levels of p63 and VDR in 
three SCC subtypes demonstrated a statistically significant increase in both p63 and VDR  
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Figure 29: Representative pictures of VDR and p63 increased expression in non-
melanoma skin cancer. Panels show representative images taken at a 20x magnification 
of normal skin, precursors to squamous cell carcinoma, squamous cell carcinoma (SCC) 
and basal cell carcinoma (BCC) from formalin fixed, paraffin-embedded human skin 
stained for p63 and VDR (scale bar = 20 μm). (Hill et al., 2015). 
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Figure 30: Increased VDR and p63 expression in non-melanoma skin cancer. 
Quantitation of p63 (A) and VDR (B) levels from 49 normal skin samples, 59 precursors 
to SCC samples, 53 SCC samples and 54 BCC samples are plotted. Y-axis represents the 
mean fluorescent intensity, normalized to background, in arbitrary units. Error bars 
represent standard error. *= p ≤ 0.05 compared to normal skin. (Hill et al., 2015). 
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Figure 31: Increased p63 expression correlates with increased VDR expression in 
NMSC.  Linear regression plot of p63 and VDR average mean fluorescent intensity per 
tissue of 49 normal skin samples, 59 precursors to SCC samples, 53 SCC samples and 54 
BCC samples. Y-axis represents the mean fluorescent intensity of VDR, normalized to 
background, in arbitrary units. X-axis represents the mean fluorescent intensity of p63, 
normalized to background, in arbitrary units.   
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Figure 32: VDR and p63 overexpression in Precursors to Squamous Cell 
Carcinoma. Panels show representative images taken at a 20x magnification (scale bar = 
20 μm) of normal skin, Actinic Keratosis, Acantholytic Actinic Keratosis, Acantholytic 
and Hyperplastic Actinic Keratosis, Hyperplastic Actinic Keratosis, Squamous cell 
carcinoma in situ and Bowenoid Actinic Keratosis from formalin fixed, paraffin-
embedded human skin stained for p63 and VDR.  
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Figure 33: Quantitation of VDR and p63 overexpression in Precursors to Squamous 
Cell Carcinoma. Quantitation of p63 (A) and VDR (B) levels from 49 normal skin 
samples, 6 Acantholytic Actinic Keratosis samples, 22 Actinic Keratosis samples, 10 
Actinic Keratosis Acantholytic Hyperplastic samples, 15 Hyperplastic Actinic Keratosis 
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samples, 4 Squamous cell carcinoma in situ samples and 2 Bowenoid Actinic Keratosis 
samples are plotted. Y-axis represents the mean fluorescent intensity, normalized to 
background, in arbitrary units. Error bars represent standard error. *= p ≤ 0.05 compared 
to normal skin. 
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expression in all three of SCC subtypes (SCC-Superficial, Perineural Invasion SCC and 
SCC) when compared to normal skin (Figure 34 and Figure 35). Intriguingly, the 
superficial squamous cell carcinoma examined showed an increase in p63 and VDR 
expression compared to non-superficial SCC (Figure 35), indicating that the more 
invasive cancers have reduced levels of p63 and VDR. Although all subtypes of BCC 
showed a significant increase in p63 and VDR levels when compared to normal skin, 
nodular basal cell carcinomas (NBCC), superficial basal cell carcinomas (SBCC) and 
nodular and infiltrative basal cell carcinoma (NIBCC) expressed higher levels of p63 and 
VDR compared to infiltrative basal cell carcinomas (BCCI) (Figure 36 and Figure 37). 
Taken together, these results demonstrate a concomitant increase in both p63 and VDR 
levels in non-melanoma skin cancers, suggesting that increased levels of p63 and VDR 
might be responsible for increased proliferation upon exposure to VD3 in non-melanoma 
skin cancer.  
I. Mutant p53 alleles H179Y  and R282W positively regulate ΔNp63α 
 Previously, mutant p53 was shown to interact with VDR and alter the 
transcriptional activity of VDR promoting tumorigenesis (Stambolsky et al., 2010). Our 
data shows that VDR increases the expression of the Np63 oncogene. Since, mutant 
p53 can determine the transcriptional activity of VDR and VDR positively regulates 
Np63, I wanted to determine the role of mutant p53 in VDR mediated increase in 
Np63 expression (Stambolsky et al., 2010). Several studies have shown that mutant 
p53 down-regulates Np63 activity leading to increased tumorigeneis  
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Figure 34: VDR and p63 overexpression in different subtypes of Squamous Cell 
Carcinoma. Panels show representative images taken at a 20x magnification (scale bar = 
20 μm) of normal skin, SCC-Superficial, SCC from AK background, Perineural Invasion 
SCC and SCC from formalin fixed, paraffin-embedded human skin stained for p63 and 
VDR.  
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Figure 35: Quantitation of VDR and p63 overexpression in different subtypes of 
SCC. Quantitation of p63 and VDR levels from 49 normal skin samples; 13 SCC-
Superficial samples, 3 Perineural Invasion SCC samples and 37 SCC samples are plotted. 
Y-axis represents the mean fluorescent intensity, normalized to background, in arbitrary 
units. Error bars represent standard error. *= p ≤ 0.05 compared to normal skin. 
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Figure 36: VDR and p63 are overexpressed in different subtypes of Basal Cell 
Carcinoma. Panels show representative images taken at a 20x magnification (scale bar = 
20 μm) of normal skin, BCC-Infiltrative, BCC-Nodular, BCC- Nodular and Infiltrative 
and BCC-Superficial from formalin fixed, paraffin-embedded human skin stained for p63 
and VDR.  
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Figure 37: VDR and p63 show significant overexpression in different subtypes of 
Basal Cell Carcinoma. Quantitation of p63 and VDR levels from 49 normal skin 
samples, 4 BCC-Infiltrative samples, 29 BCC-Nodular samples, 6 BCC- Nodular and 
Infiltrative samples and 15 BCC-Superficial samples are plotted. Y-axis represents the 
mean fluorescent intensity, normalized to background, in arbitrary units. Error bars 
represent standard error. *= p ≤ 0.05 compared to normal skin.  
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(Shaulian et al., 1992; Gaiddon et al., 2001; Li, Y. & Prives, 2007; Adorno et al., 2009; 
Liu et al., 2009; Marine & Berx, 2009; Muller et al., 2009; Rokaeus et al., 2010; 
Girardini et al., 2011; Neilsen et al., 2011; Neilsen et al., 2013). Mutant p53 regulation of 
VDR transcriptional activity could represent a novel mechanism by which mutant p53 
regulates Np63 expression. To determine if mutant p53 up-regulates Np63, I 
studied effects of p53 knockdown in HaCaT cells that harbor two mutant alleles of p53 at 
H179Y and R282W, these two mutant alleles are known to increase proliferation and 
chemo-resistance, respectively (Mueller et al., 2001; Yang, D. et al., 2007; Li, X. et al., 
2012; Xu et al., 2014). As expected, cells transfected with siRNA against p53 showed a 
significant reduction in p53 expression (Figure 38). As shown in Figure 38, loss of 
mutant p53 in HaCaT cells also led to a concomitant reduction of both Np63 transcript 
and protein levels. To confirm that loss of mutant p53 reduces Np63 levels, I silenced 
p53 with siRNA specific to p53 and measured changes in p53 and Np63 protein via 
immunofluorescence. Consistent with immunoblot analysis, immunofluorescence 
staining of Np63 following loss of p53 showed a reduction in Np63 expression 
(Figure 39). Taken together, these data indicate that the loss of mutant p53 leads to a 
reduction in Np63 transcript and protein expression. 
Since mutant p53 was shown to regulate the activity of VDR, I next examined the 
effect of the combined loss of both VDR and mutant p53 on Np63 levels. I transfected 
HaCaT cells with non-silencing control siRNA or siRNA against p53 and VDR alone or 
together. Following transfections I measured the change in Np63, VDR and p53 
protein expression via immunoblot analysis. As expected and previously shown in Figure 
8, loss of VDR leads to a dramatic reduction in Np63 protein expression (Figure 40A).   
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Figure 38: Loss of mutant p53 led to a reduction in ΔNp63α levels. HaCaT cells were 
transfected with non-silencing control siRNA and siRNA against p53. Changes in 
transcript (Top panel) and protein (Bottom panel) expression of p63 and p53 were 
measured by qRT-PCR (*=p values ≤ 0.05) and immunoblot analysis, respectively. RNA 
levels were measured with assays on demand (AODs) specific to p63, p53 and GAPDH. 
GAPDH was used as an endogenous control. Protein expression was detected using p63 
and p53 specific antibodies. Detection of β-actin with a β-actin specific antibody was 
used as a loading control. The fold-change in protein levels, relative to NSC transfected 
cells, is listed above each band.  
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Figure 39: Mutant p53 is important for ΔNp63α protein expression. Top panel: 
HaCaT cells were transfected with non-silencing control siRNA and siRNA against p53 
followed by detection of p63α and p53 by immunofluorescence. Bottom panel: average 
mean fluorescent intensity of immunofluorescence staining for p63 and p53 in HaCaT. 
Error bars represent standard error of the mean. *=p values ≤ 0.05 compared to vehicle 
control cells. Each sample consists of a 100 counted cells per experiment. 
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Additionally, loss of mutant p53 did not only decrease Np63 levels but also reduced 
VDR protein expression when compared to NSC transfected samples (Figure 40A). The 
combined knockdown of VDR and mutant p53 together further reduced Np63 protein 
expression when compared to cells transfected with siRNA against p53 or VDR alone 
(Figure 40A). Having established that mutant p53 and VDR up-regulates Np63 protein 
expression, I next wanted to determine if mutant p53 in cooperation with VDR up-
regulates Np63 transcript levels. To this end, I again knocked down the expression of 
VDR and p53 expression alone or together and measured changes in p63, VDR and p53 
transcript level by qRT-PCR. As expected, there was a significant reduction in mutant 
p53 transcript levels following transfection with siRNA against p53 (Figure 40B). 
Knockdown of mutant p53 resulted in a reduction in p63 transcript levels in HaCaT cells 
(Figure 40B) indicating that mutant p53 may be regulating Np63 at the transcript 
level. Consistent with previous findings, loss of VDR led to a reduction in both p63 and 
VDR transcript levels (Figure 40B). Knockdown of p53 and VDR together led to a 
significant decrease in both mutant p53 and VDR transcript levels (Figure 40B). 
Combined knockdown of both mutant p53 and VDR together did not further reduce p63 
transcript levels beyond those observed with individual VDR or mutant p53 knockdown, 
suggesting that mutant p53 may up-regulate Np63 expression at both the transcript 
and protein levels via VDR. 
J. Mutant p53 forms a complex with VDR 
 Previously, the mutant p53 allele R175H was shown to form a complex with VDR 
(Stambolsky et al., 2010). The interaction between VDR and mutant p53 was shown to 
reside in the DNA binding domain (DBD) of mutant p53 R175H  
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Figure 40: Loss of mutant p53 and/or VDR reduced ΔNp63α protein and transcript 
expression. HaCaT cells were transfected with control siRNA, or siVDR, sip53 or both 
sip53 and siVDR.  Changes in protein (A) and transcript (B) levels of Np63, VDR and 
p53 were measured by immunoblot and qRT-PCR analysis, respectively. The fold-change 
in protein levels, relative to NSC transfected cells, is listed above each band. 
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(Stambolsky et al., 2010). The binding of mutant p53 to VDR was shown to alter 
VDR/VD3 nuclear signaling, resulting in changes in gene expression such as Mitogen 
Activated Protein Kinase Kinase 5 (MAP2K5) and Fibroblast Growth Factor Receptor 2 
(FGFR2) (Stambolsky et al., 2010). I chose to evaluate whether the mutant p53 H179Y 
and R282W alleles, both commonly associated with UV radiation (Dumaz et al., 1993; 
Ziegler et al., 1993), form a complex with VDR to increase the expression of Np63. I 
performed immunoprecipitation studies wherein I immunoprecipitated mutant p53 and 
measured co-precipitation of VDR by immunoblot analysis in HaCaT cells.  As expected, 
immunoprecipitation with a p53 specific antibody showed precipitation of mutant p53 
from HaCaT cells, while immunoprecipitation of mutant p53 also led to co-precipitation 
of VDR (Figure 41).  This data indicates that mutant p53 H179Y or R282W alleles or 
both in combination form a complex with VDR. 
K. Mutant p53 plays a role in VD3-mediated increase in Np63 
 Since, mutant p53 has been implicated in VDR target gene regulation in the 
presence of VD3 (Stambolsky et al., 2010) and I have shown that VDR and VD3 increase 
Np63 expression, I next examined the role of mutant p53 on VD3 mediated up-
regulation of Np63. To address this I measured changes in Np63 protein levels by 
immunoblot analysis following treatment with vehicle control, 10 nM VD3 or 100 nM 
VD3 for 24 hours in presence or absence of mutant p53 knockdown. As expected, 10 nM 
VD3 increased Np63 protein levels in HaCaT and HaCaT II-4 cells transfected with 
NSC (Figure 42).  Consistent with previous reports from our laboratory, expression of 
VDR increased in a dose dependent manner following VD3 treatment in HaCaT cells 
(Kommagani et al., 2006; Kommagani et al., 2009) (Figure 42A). Both doses of VD3 also   
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Figure 41: Endogenous VDR forms a complex with endogenous mutant p53.  HaCaT 
cells were grown to 90% confluency. Whole extracts from HaCaTs were subject to 
immunoprecipitation with a p53 specific antibody or myc-tag antibody as a control 
followed by immunoblot analysis to detect p53 and VDR expression with antibodies 
specific to p53 and VDR. 
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Figure 42: Knockdown of mutant p53 (H179Y and R282W) reduced VD3-mediated 
increase in ΔNp63α expression.  HaCaT (A) and HaCaT II-4 (B) cells were transfected 
with non-silencing control siRNA or siRNA against p53 followed by treatment with 
vehicle control, 10 nM or 100 nM VD3 for 24 hours. The change in Np63, p53 and 
VDR was measured by immunoblot analysis. The fold-change in protein levels, relative 
to cells treated with vehicle control following transfection with NSC is listed below each 
band.  
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led to an increase in VDR protein expression in HaCaT II- 4 cells (Figure 42B). HaCaT 
and HaCaT II-4 cells transfected with siRNA against p53 showed a significant reduction 
in mutant p53 levels as expected, which coincided with a reduction in Np63 
expression in these two cell lines, regardless of VD3 treatment (Figure 42). Furthermore, 
loss of mutant p53 also reduced VD3 mediated stabilization of VDR (Figure 42), 
indicating that mutant p53 is also involved in regulating VDR expression. Mutant p53 
regulation of VDR is potential mechanism by which mutant p53 indirectly up-regulates 
Np63. Taken together, our data suggests that mutant p53 is important for VD3-
mediated increases in Np63 protein levels. 
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IV. DISCUSSION 
A. VDR and 1, 25-dihydroxyvitamin D3 up-regulate Np63 protein expression 
and activity via Akt and p38 MAPK activation.  
 Proliferation followed by simultaneous differentiation and inhibition of 
proliferation are noteworthy characteristics of the skin, allowing for the development of 
each layer of the epidermis (Fuchs & Raghavan, 2002). Delineating the mechanisms 
involved in activating or preventing keratinocyte proliferation remains critical for 
improving our understanding of non-melanoma skin cancer (NMSC). Np63 is the 
most robustly expressed p63 isoform in the basal layer of the skin, where Np63 is 
known to up-regulate genes involved in proliferation (Yang, A. et al., 1998; Mills et al., 
1999). In fact, Np63 is considered to be the master regulator of epithelial stemness, 
and it is likely involved in multiple pathways that stimulate proliferation (Melino et al., 
2015). Overexpression of Np63 is seen in many non-melanoma skin cancer lesions, 
such as the lesions found in squamous cell carcinoma (Choi et al., 2002; Di Como et al., 
2002; Bircan et al., 2006; Sakiz et al., 2009). Despite its broad role in controlling 
epithelial fate, very little is known about the upstream regulators of Np63.   
Our laboratory has previously shown that Np63 positively regulates VDR 
expression (Kommagani et al., 2006). VDR is expressed in the basal layer of the skin and 
is well known for its role in differentiation and calcium homeostasis (Dusso et al., 2005; 
Haussler et al., 2012). Previous work showed that VDR functions independently of VD3 
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to activate basal level transcription of 24-hydroxylase (Ellison et al., 2007). Here I show 
that VDR is essential for maintaining basal levels of Np63 transcription in a ligand 
independent manner, thus suggesting that VDR may initiate proliferation indirectly 
through Np63 (Figure 8).  
VD3 has been considered a chemotherapeutic adjuvant in the treatment of a 
number of cancers (Asagami et al., 1996; Zhao et al., 1997; Iseki et al., 1999; Reis-Filho 
et al., 2002; Lo Muzio et al., 2005; Bircan et al., 2006; Cheng et al., 2009). Our study 
indicates that reduction in Np63 levels could improve the therapeutic potential of VD3 
in the treatment of non-melanoma skin cancers. This notion is supported by previous data 
demonstrating that Np63 confers cisplatin resistance in a number of cancers such as 
head and neck squamous cell carcinomas and breast cancers (DeYoung et al., 2006; 
Leong et al., 2007; Sen et al., 2011), thus suggesting that controlling Np63 levels may 
be beneficial in treating epithelial cancers (DeYoung et al., 2006; Leong et al., 2007; Sen 
et al., 2011) 
Therapeutic potential of low dose VD3 
Low levels of VD3 has been shown to correlate with high-grade prostate cancer in 
men over 55 years of age (Schenk et al., 2014), indicating that low levels of VD3 may 
have a profound effect on cancer progression.  Our findings herein suggest a novel role 
for VDR/VD3 in regulating proliferation and cell survival through the regulation of 
Np63. I found that VD3 increases the expression of Np63 transcript and protein in 
the presence of its receptor VDR (Figure 11) and increases keratinocyte proliferation 
(Figures 11 and 20), but only at low doses of VD3.  This finding mirrors the observed role 
for VD3 in prostate cancer, which has shown that low levels of VD3 increase prostate 
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tumor cell proliferation and suggests that low-levels of VD3 may mediate the resulting 
downstream increase in proliferation through its effects on Np63 (Figure 20). Our data 
suggest that low levels of VD3 may enhance cancer progression, suggesting the level of 
VD3 is extremely important in eliciting the appropriate response as a chemotherapeutic 
adjuvant.  
Therapeutic potential of high dose VD3 
High levels of serum VD3 are associated with a decreased risk of breast cancer 
and colon cancer mortality (Anic et al., 2014; Kim & Je, 2014; Zgaga et al., 2014; 
Weinstein et al., 2015). Moreover, high level VD3 therapy has been used as a 
chemotherapeutic adjuvant for patients with prostate cancer (Zhuang & Burnstein, 1998). 
Here I show that high doses of VD3 do not increase Np63 levels and correlate with a 
reduction in cell proliferation (Figure 11 and Figure20). Consequently, the ligand 
requirement of VDR mediated transcription might be situation specific allowing VDR to 
up-regulate genes essential for cell homeostasis in the presence or absence of VD3, 
thereby providing an additional layer by which keratinocyte proliferation is sustained in 
response to varying environmental settings.  
Non-genomic contributions of VD3 to Np63 function 
VDR and VD3 up or down-regulate many transcriptional targets and cellular 
processes. VDR and VD3 have non-genomic functions known as rapid response activities 
in the cell which include insulin secretion, smooth muscle migration and opening calcium 
and chloride channels (Haussler et al., 2011).  VD3 has also been shown to activate a 
number of kinases such as Akt, Protein kinase A (PKA) and Protein Kinase C (PKC) 
through the rapid response-signaling pathway (Zhang, Y. et al., 2006; Deeb et al., 2007; 
 100 
Zhang, X. & Zanello, 2008; Haussler et al., 2011). Here I demonstrate that VD3 enhances 
Np63 expression in a non-genomic manner by activating p38 MAPK thereby 
increasing Np63 protein levels (Figure 17, Figure 18 and Figure 19). This increase in 
Np63 protein levels was shown to be dependent on VD3 concentration as only low 
doses of VD3 were able to increase Np63 levels (Figures 10-12). Increased Np63 
protein induced by low doses of VD3 also correlated with an increase in cellular 
proliferation in keratinocytes (Figure 20), thus implicating low level VD3 as an mediator 
of the increased proliferation seen in cancer cells. Interestingly, knockdown of Np63 
or VDR reduced cell proliferation at all doses of VD3 tested (Figure 24).   
Upstream regulators of the VD3 /Np63 pathway 
Previous reports have shown VD3 can activate the AKT pathway, a well-
established survival pathway (Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008). 
Moreover, AKT has been reported to positively regulate the expression of Np63 
(Segrelles et al., 2006; Ogawa et al., 2008). Our lab previously reported that Np63 
represses PTEN transcription leading to increased AKT activity (Leonard et al., 2011). 
Here I show that both AKT and VDR plus VD3 contribute to the regulation of Np63 
protein expression (Figure 16). Furthermore, inhibition of Akt reduced the VD3-mediated 
increase in keratinocyte proliferation, which correlated with the effects on Np63 
protein level (Figure 25). Our data supports the finding that VD3 increases Akt activation, 
but that this increase is not the sole mechanism that leads to increased Np63 protein 
levels.  While Akt plays a major role in the regulation of basal Np63 levels, VD3-
mediated increases in Akt activation only play a minor role in the regulation of Np63 
protein. 
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Previous findings have shown that VD3 activates the MAP kinase p38 in a non-
genomic pathway leading to the increased proliferation of muscle cells (Buitrago, C. G. et 
al., 2006; Buitrago, C. & Boland, 2010). VD3 was shown to bind to VDR in a complex 
with caveolin-1 at the plasma membrane to stimulate a non-genomic VD3 response 
(Buitrago, C. & Boland, 2010). Once VD3 binds to membrane associated VDR and 
caveolin-1, VDR recruits the tyrosine kinase Src for full activation of p38 MAPK 
(Buitrago, C. & Boland, 2010). Activated p38 MAPK has also been shown to lead to an 
increase in Np63 protein (Cheng et al., 2009). In my study, I show that inhibition of 
p38 MAPK activation eliminates low dose VD3-mediated increases in Np63 (Figure 
18 and Figure 19). COX-2, a target of p38 MAPK, is also up-regulated in non-melanoma 
skin cancer, which further supports a role for activated p38 MAPK in these cancers and 
shows that p38 MAPK can up-regulate its target genes, such as Np63 shown here 
(Bachelor & Bowden, 2004). Our data indicates that inhibition of p38 MAPK partially 
abrogates the observed VD3-mediated increases in Np63 suggesting that p38 MAPK is 
a potential pathway to target in conjunction with current chemotherapeutic regimen in 
cancers such as NMSC.  
VD3 and Np63 expression in non-melanoma skin cancers 
Both VDR and p63 have been separately shown to be overexpressed in non-
melanoma skin cancers (Hibi et al., 2000; Choi et al., 2002; Di Como et al., 2002; 
Mitschele et al., 2004; Reichrath et al., 2004; Bircan et al., 2006; Sakiz et al., 2009). In 
this study, I demonstrated that both p63 and VDR expression are increased in the same 
tissues of patients with BCC, SCC or precursor lesions to SCC (Figure 29). Interestingly, 
only VDR was overexpressed in actinic keratose (AK) and only Np63 protein showed 
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an increase in acantholytic and hyperplastic actinic keratose (AKAH) (Figure 32). Since 
VDR positively regulates Np63 expression, it is feasible that the onset of AK 
promotes the expression of VDR, which in turn induces Np63 expression as lesions 
progress toward SCC. Alternatively, it could be argued that overexpression of Np63 
positively regulates VDR expression resulting in the induction of AKAH, consistent with 
AKAH being a thicker and more proliferative lesion compared to AK (Goldberg et al., 
1994). In this scenario, the initial Np63 leads to increased VDR expression as the 
lesion progresses to SCC. Given the role of p63 and VDR in the inhibition of cell 
invasion, it came as a surprise that both VDR and p63 were highly expressed in the more 
invasive SCC tumor samples compared to the SCC precursor samples (Figure 34). 
Mutant p53 was previously shown to inhibit the p63-mediated reduction in cell migration 
and invasion (Girardini et al., 2011; Liu et al., 2011; Neilsen et al., 2013). Furthermore, 
mutant p53 can selectively alter the transcriptional activity of other transcription factors 
leading to phenotypic changes that promote tumorigenesis (Stambolsky et al., 2010; 
Girardini et al., 2011; Liu et al., 2011; Neilsen et al., 2013). In my study, I found that 
VDR led to increased levels of Np63, which also correlated with tumor progression.  
Mutant p53 is highly expressed in many NMSC lesions and inhibits Np63 function, 
and should therefore serve to increase the invasive properties of SCC. Consistent with 
previous reports that p63 is increased in BCC (Hibi et al., 2000; Choi et al., 2002; Di 
Como et al., 2002; Mitschele et al., 2004), I similarly found that p63 is increased in BCC 
and this increases correlates with an increase in VDR in these tumors (Figure 36).  
These results imply that elevated levels of VDR are not an indication of a good 
prognostic outcome since I observed higher levels of VDR in more invasive SCC 
 103 
samples. Therefore, increased Np63 and VDR expression in NMSC may serve as 
biomarkers for these types of cancers.  Np63 and VDR expression could also be used 
as predictors of the patient response to VD3 treatment as a chemotherapeutic agent only 
or in conjunction with other chemotherapeutic treatments. VDR and VD3, which are both 
considered important in cancer prevention, are shown here to also play a role in the 
regulation of oncogenic Np63 which correlates with an increase in keratinocyte 
proliferation at low VD3 concentration, bringing to light a potential problem with the use 
of VD3 in cancer prevention and treatment (Audo et al., 2003; Bikle et al., 2006). 
Together, these results suggest that VD3 can play a growth stimulatory role in the 
presence of VDR in keratinocytes cells by regulating the expression of Np63. Our data 
suggests that monitoring VD3 concentration in cancer treatment regimens will be critical 
to reduce cancer cell growth.  This finding is reinforced by a recent study which 
demonstrated that tumors from SKH-1 showed an increase in p63 expression with 
increasing concentration of dietary vitamin D (Hill et al., 2014). Since VD3 action 
appears to be dose-dependent, ensuring high enough doses of VD3 are getting into the 
tumor cells to reduce Np63 expression and the resulting proliferation will be critical to 
its successful implementation as a chemotherapeutic adjuvant. 
B. VDR/VD3 mediated up-regulation of Np63 expression is dependent on mutant 
p53. 
 Previous studies have shown that vitamin D supplementation protects against skin 
cancer (Garland et al., 2009; Ness et al., 2015).  UVB radiation with a wavelength of 
290-330 nM is required for VD3 production in the skin (Garland et al., 2009; Bikle, 2012; 
Ness et al., 2015), yet ultraviolet (UV) is the major cause of skin cancer (Bikle, 2012; 
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Gordon, 2013; Surdu, 2014). Interestingly, this is the same wavelength of radiation that 
induces many of the mutations found in the p53 gene (Dumaz et al., 1993; Ziegler et al., 
1993). In the skin UVB irradiation leads to the production of thymine-thymine dimer, 
which are a cys-syn cyclobutane pyrimidine dimer that arise from a cytosine to thymine 
substitution induce by the UVB energy (Dumaz et al., 1993; Ziegler et al., 1993). A 
number of these UV induced mutations are found in the p53 gene in non-melanoma skin 
cancer (Ziegler et al., 1993). Since p53 is highly mutated in skin cancer and non-
melanoma skin cancers show an increased level of Np63, it is vital to determine the 
interplay between the two proteins in skin cancer.   
Role of mutant p53 in the regulation of the VD3/Np63 pathway 
 Mutant p53 function is dependent on the specific mutation. While some mutant 
p53 proteins lead to loss of function, some lead to gain of function and others function 
similar to wild type p53 (Freed-Pastor & Prives, 2012). Defining the mechanism of action 
of each mutant p53 allele remains an important task to understand underlying role each 
plays in cancer. Previous work has shown an interplay between VDR and p53 R175H 
(Stambolsky et al., 2010) but the p53 R175H is not a mutant that arises from a cytosine to 
thymidine C-T transition, which is a characteristic of UV induced mutations. In fact, the 
p53 R175H is a G-A mutation, which is commonly induced in cancer to eliminate the 
CpG methylation site in the p53 gene or is a result of an unrepaired mutation that was 
substituted with an adenosine during replication (Dumaz et al., 1993; Ziegler et al., 
1993). To better understand mutant p53 proteins arising from UVB damage, I evaluated 
mutant p53 function in HaCaT cells carrying two mutant p53 alleles, H179Y (resulting 
from CC to TT mutation) and R282W (resulting from a C to T mutation) (Dumaz et al., 
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1993; Ziegler et al., 1993).  I found that loss of mutant p53 significantly reduced Np63 
expression levels (Figure 38) and loss of Np63 resulted in a decrease in keratinocyte 
proliferation (Figure 23).  Conversely, I also showed that the mutant alleles of p53 and 
VDR positively regulate Np63 expression (Figures 39), potentially via mutant p53 
modulation of VDR regulation of Np63 as described earlier (Stambolsky et al., 2010).  
Based on our data, however, it is unlikely that mutant p53 solely increases Np63 
transcript levels (Figure 40). Loss of mutant p53 in the absence of VDR also led to a 
further reduction in Np63 protein levels compared to the loss of mutant p53 or VDR 
alone (Figure 40). Thus indicating that mutant p53 in the presence of VDR up-regulates 
Np63 at the protein level potentially through the stabilization of Np63 protein as 
the combined knockdown of mutant p53 and VDR did not lead to a further reduce in p63 
transcript. Moreover, I found that mutant p53 was important for VD3-mediated increase 
in Np63 (Figure 42).  
 The interaction between VDR and mutant p53 leads to changes in VDR target 
transactivation wherein p53 R175H increases the expression of genes involved in 
proliferation and cell survival but inhibits pro-apoptotic genes (Stambolsky et al., 2010). 
Here I show that p53 H179Y and/or R282W proteins form a complex with VDR (Figure 
41). This complex might have the ability to increase the expression of Np63.  In 
NMSC, Np63 expression has been shown to increase tumor proliferation (Leonard et 
al., 2011; Leonard et al., 2013; Li, C. et al., 2013; Ripamonti et al., 2013), consistent 
with our data which showed that loss of Np63 leads to a decrease in keratinocyte 
proliferation (Figure 23). Interestingly, the overexpression of mutant p53 H179Y allele 
has been shown to increase human embryonic lung fibroblast proliferation by promoting 
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the expression of cyclin A1 and cyclin dependent kinase 4 (CDK4) (Yang, D. et al., 
2007). Increased mutant p53 and increased Np63 expression in the presence of VDR 
and VD3 led to increased keratinocyte proliferation.  Furthermore, mutant p53 alleles 
H179Y and R282W were critical for the VD3-mediated increase in Np63 expression in 
keratinocytes (Figure 42), indicating a potential interplay between VDR/VD3 signaling, 
mutant p53 signaling and Np63 signaling that could play a major role in the onset of 
NMSC and many other cancers of epithelial origin.   
Other potential mediators of VD3/Np63 pathway in the presence of mutant p53 
VDR and VD3 have rapid response signaling that occur independently of 
transcription, so mutant p53 could induce the activation of specific kinases which 
stabilize Np63 protein expression such as p38 MAPK, cAbl and Akt (Zhuang & 
Burnstein, 1998; Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008; Yuan et al., 2010; 
Haussler et al., 2011) by modulating VD3 rapid response signaling cascades, although 
further testing is required to confirm this hypothesis.  
Previous reports suggest that mutant p53-mediated increase in Np63 lead to a 
corresponding increase in the expression of Heat Shock Protein 70 (HSP70) and a 
resulting stabilization of mutant p53 expression (Wu et al., 2005; Wiech et al., 2012). 
Furthermore, evidence in the kidney suggests that VDR potentially up-regulates HSP70 
expression (Garcia et al., 2014), raising the possibility that VDR could increase HSP70 
indirectly through VD3/VDR-mediated increases in Np63 expression (Figure 11) 
leading to increased mutant p53 expression and tumorigenesis.  
Potential interactions of VD3 with p53 and Mdm2 
 107 
 Not all tumors carry a p53 mutation; some express wild type p53 while other 
tumors show loss of wild type p53 expression all together (Stambolsky et al., 2010; 
Freed-Pastor & Prives, 2012).  The complete loss of p53 expression by deletion of the 
gene or epigenetic change to the gene locus (Thompson et al., 1992) frequently arises in 
cancer.  As shown in Figure 8, loss of VDR in the presence of wild type p53 led to a 
reduction in Np63 transcript and protein expression, but wild type p53 expression was 
very low in these primary keratinocyte cells. When wild type p53 is stabilized as a result 
of a stressor, the stability of Np63 protein expression in this environment will result in 
a balance between wild type p53 mediated reduction in Np63 and VDR/VD3-mediated 
increase in Np63 (Galli et al., 2010).    
Wild type p53 leads to Np63 degradation by increasing the level of Mdm2, 
which binds to Np63 and causes its translocation to the cytoplasm (Galli et al., 2010). 
Translocation of Np63 to the cytosol brings Np63 in close proximity to the E3-
ubiquitin ligase Fbw7 for degradation (Galli et al., 2010). Interestingly, VD3 also 
enhances Fbw7 ubiquitination, but this enhanced activity was only shown at 100 nM 
VD3, and 100 nM of VD3 did not increase Np63 expression in our keratinocyte study 
(Figure 11) (Fekrmandi et al., 2015). The level of VD3 in cells could be the driver that 
initiates cell proliferation or differentiation, cell cycle arrest or apoptosis. Tumor 
proliferation could be enhanced as a result of a tumor cell reducing the concentration of 
VD3 in a cell to promote proliferation via increased Np63 and reduce wild type p53 
levels by up regulating Mdm2 (Haupt, Y. et al., 1997). VDR and VD3 increase Mdm2 
levels only the presence of wild-type p53 (Fekrmandi et al., 2015).  Therefore, in the 
presence of wild type p53 and low VD3, a reduction in wild p53 occurs through Mdm2, 
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thus leading to the VDR and VD3-mediated increase in Np63 expression and the 
observed enhancement in proliferation.  
Potential mechanism of VDR mediated increase in Np63 in p53-null cells  
Tumors that are p53-null can still induce many of the functions of wild-type p53 
harboring tumors due to the presence of p73. p73, a member of the p53 family, has 
distinct functions in neuronal development, proliferation and tumor suppression (Roos & 
Kaina, 2006).  Like Np63, TAp73 and TAp73β increase the expression of VDR in 
p53 wild type cells and p53-null cells (Kommagani et al., 2007). TAp73 and TAp73β 
also induces the intrinsic apoptotic pathway by increasing the expression of PUMA, 
leading to Bax activation and cytochrome C release from the mitochondria (Roos & 
Kaina, 2006). Thus, it is likely that in a p53-null tumor, the balance between proliferation 
and cell death is mediated by p73. Our findings suggest that increased TAp73 and 
TAp73β potentially leads to increases in Np63 via the increased expression of VDR in 
both cells that express wild type p53 or are null for p53.  Unfortunately, Np63 has 
been shown to inhibit TAp73 activity and thereby apoptosis (Roos & Kaina, 2006). 
Interestingly, treatment with DNA damage inducing agents like etoposide not only 
increases p73 message via E2F1 but also stabilizes p73 expression via activation of Chk2 
(Roos & Kaina, 2006). Following activation, the Chk2 upstream regulator ATM 
phosphorylates Np63 leading to degradation of Np63 (Matsuoka et al., 1998). 
More importantly, increased Np63 expression leads to an increase in the expression 
levels of ATM (Craig et al., 2010). Therefore, in a cell lacking p53, p73 would be 
expected to lead to increased VDR expression and a corresponding increase in Np63, 
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which would either inhibit p73 pro-apoptotic activity or increase ATM levels thereby 
leading to its own degradation.  
C. Conclusions  
 VDR and VD3 play a central role in cancer through modulation of cell 
survival and apoptosis (Deeb et al., 2007).  The work presented in this dissertation 
elucidated multiple novel mechanisms by which VD3 and VDR function to increase 
Np63 protein expression (Figure 43). I showed that VDR increases Np63 
expression. I also found that low doses of VD3 cause an increase in Np63 protein in a 
dose dependent manner up to 10 nM VD3 (Figure 10) leading to increased keratinocyte 
proliferation. I further showed that VDR-mediated increases in Np63 are critical for 
VD3-mediated increases in proliferation, thus advancing our understanding of the 
mechanism by which VDR and VD3 lead to increased keratinocyte proliferation. Further, 
I showed that both p38 MAPK and Akt modulate VD3-mediated increases in Np63 
and the downstream increase in cell proliferation.  The interplay between VDR and 
mutant p53 showed that not only dose VDR play an important role in VD3 mediated 
increase in Np63 but mutant p53 expression was important as well.  Interestingly, both 
Np63 and VDR levels were increased in NMSC samples compared to controls 
indicating a potential interplay between VDR and Np63 function that leads to an 
increase in cancer cell survival. 
 It has become increasingly clear we in the VD3 field still have a rudimentary 
understanding of the interplay between p53, Np63 and VD3/VDR pathways and how 
they play off each   
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Figure 43: VDR/VD3 mediated regulation of Np63. VD3 stimulates cell growth in 
the presence of VDR with (A) or without (B) mutant p53 complex in keratinocytes cells 
by regulating the expression of Np63 via Akt and p38. 1 (Kommagani et al., 2006), 2 
(Barbieri et al., 2003), and 3 (Cheng et al., 2009). 
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other to promote tumor cell survival or lead to tumor cell death.  Delineating the interplay 
between multiple pathways is critical to our understanding of cancer progression, 
metastasis and chemoresistance. 
D. Concluding remarks 
 VD3 deficiency is associated with increased risk of cardiovascular disease, 
hypertension, stroke, diabetes, multiple sclerosis, rheumatoid arthritis, macular 
degeneration, mental illness, chronic pain and cancer (Cannell & Hollis, 2008). The 
preferred method to treat VD3 deficiency is supplementation with 25-hydroxy-vitamin D 
(25(OH)D) or pre-VD3 (cholecalciferol) (Cannell & Hollis, 2008). Our data and others 
suggest that the level of VD3 is critical to induce the preferred response such as 
prevention of cancer. For example, in certain cancers high serum levels of VD3 such as 
≥95 nmol/L were sufficient to reduce colon cancer risk by 55% compared to 40 nmol/L 
(Freedman et al., 2007). Furthermore, lower levels of serum VD3, those less than 50 
nmol/L in patients with breast cancer are linked with increased metastases and a reduced 
survival rate (Garland et al., 2009). Thus, 25-hydroxy-vitamin D levels (serum VD3) and 
maintaining a sufficient level of serum VD3 is important when considering the 
appropriate concentration of VD3 for supplementation. The recommended serum VD3 
level is 30 nmol/L to 50 nmol/L, which is generally achieved by 600 international units 
(IU) of supplemented cholecalciferol or daily UVB exposure (Ross et al., 2011).  
Unfortunately, the recommended level of serum VD3 does not prevent or reduce 
mortality in colon, breast, or prostate cancer (Freedman et al., 2007; Gorham et al., 2007; 
Garland et al., 2009). Furthermore, UVB exposure has the potential to promote 
melanoma and non-melanoma skin cancers. 
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 Extremely high levels of serum VD3 can be toxic and lead to hypercalcemia. 
Hypercalcemia is an increase in serum calcium that if left untreated will lead to 
calcification of internal organs like the kidneys (Cannell & Hollis, 2008). Fortunately, for 
practitioners this is rarely ever a problem due to the time (months) and dose (≥10,000 
IU/day) of cholecalciferol that is required to induce hypercalcemia (Cannell & Hollis, 
2008). More recently Durup et al., identified a correlation between serum VD3 levels of 
≥125 nmol/L and increased risk of coronary artery disease and stroke (Durup et al., 
2015). Indicating that there is a narrow range at which VD3 is beneficial, for cancer 
prevention greater than 95 nmol/L and to prevent heart disease less than 125 nmol/L.  
 Therefore, based on our data and the literature in the field the recommended 
serum level of VD3 should be increased and kept in a narrow range between 100 and 120 
nmol/L. As such, vitamin D supplementation should be closely monitored to ensure the 
level does not drop or rise beyond a level that is advantageous to the patient.  
E. Future Directions 
This dissertation defines a novel mechanism for Np63 regulation in response to 
VDR and VD3 genomic and non-genomic signaling.  My findings suggest VD3 
concentration is a central driver of cell survival in NMSC. Since our data shows that low 
VD3 levels increase Np63 and keratinocyte proliferation (Figure 11), the next step for 
this project is to determine the mechanism by which high dose VD3 leads to decreased 
keratinocyte proliferation. A better understanding of high dose VD3 mechanism of action 
can lead to new more potent treatments that can be specifically exploited to combat 
certain cancer. Here I observe a reduced rate of proliferation with high dose VD3 (Figure 
20), thus suggesting that my data can be used translationally in the clinic to treat patients 
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with NMSC using a high dose of VD3 to reduce tumor proliferation. Interestingly, both 
topical VD3 and a VD3 analog that is in a locked confirmation to induce the rapid 
response active of VD3, showed reduce skin tumor burden in Shk1 mice further 
suggesting that VD3 can be used clinically to treat NMSC (Dixon et al., 2011). Moreover, 
VD3 stabilizes the expression of VDR and VDR play an important role in inducing 
differentiation and inhibition of migration, which further serves as to reduce 
tumorigenesis (Palmer et al., 2001; Kommagani et al., 2006). Furthermore, VDR has 
been previously shown to induce the expression of VDR target genes in a p53-dependent 
manner (Fekrmandi et al., 2015). It would be interesting to see if there are genes that are 
induced by VDR in Np63-dependent manner.  
Understanding cancer biology has become increasingly difficult with the 
identification of microRNAs (miRNA) and long non-coding RNAs (lncRNA) (Ling et 
al., 2013). Future studies should focus on miRNAs induced or inhibited by the interplay 
between VDR/Np63/mutant p53 at both 10 nM and 100 nM VD3 along with defining a 
role for p38 MAPK and Akt in the regulation of the miRNAs. Subsequently, 
identification of pathways up or down-regulated by these miRNA would help to define a 
global NMSC signaling pathway including VDR and Np63. 
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